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Edwin Carl Stage Jr. 
IMAGING GENETICS AND BIOMARKER VARIATIONS OF CLINICALLY 
DIAGNOSED ALZHEIMER’S DISEASE 
Neuroimaging biomarkers play a crucial role in our understanding of 
Alzheimer’s disease. Beyond providing a fast and accurate in vivo picture of the 
neuronal structure and biochemistry, these biomarkers make up a research 
framework, defined in a 2018 as the A(amyloid)/T(tau)/N(neurodegeneration) 
framework after three of the hallmarks of Alzheimer’s disease. I first used 
imaging measures of amyloid, tau and neurodegeneration to study clinically 
diagnosed Alzheimer’s disease. After dividing subjects into early (onset younger 
than 65) and late-onset (onset of 65 and older) amyloid-positive (AD) and 
amyloid-negative (nonAD) groups, I saw radically differing topographical 
distribution of tau and neurodegeneration. AD subjects with an early disease 
onset had a much more severe amyloid, tau and neurodegeneration than late-
onset AD. In the nonAD group, neurodegeneration was found only in early-onset 
FDG PET data and in a nonAlzheimer’s-like MRI and FDG pattern for late-onset.  
The late-onset nonAD resembled that of limbic-predominant age-related TDP-43 
encephalopathy.  
I next utilized an imaging genetics approach to associate genome-wide 
significant Alzheimer’s risk variants to structural (MRI), metabolic (FDG PET) and 
tau (tau PET) imaging biomarkers. Linear regression was used to select variants 
for each of the models and included a pooled sample, cognitively normal, mild 
cognitive impairment and dementia groups in order to fully capture the cognitive 
 ix 
spectrum from normal cognition to the most severely impaired. Model selected 
variants were replicated using voxelwise regression in an exploratory analysis of 
spatial associations for each modality.  For each imaging type, I replicated some 
associations to the biomarkers previously seen, as well as identified several 
novel associations. Several variants identified with crucial Alzheimer’s 
biomarkers may be potential future targets for drug interventions. 
Karmen K. Yoder, Ph.D., Chair 
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Chapter 1. Background and Justification 
 Alzheimer’s disease (AD) is the most common cause of dementia in the 
United States, currently affecting an estimated 5.8 million Americans, including 
as much as 10 percent of the U.S. population over the age of 65 1.  The financial 
burden of dementia in 2019 on both caregivers and patients is estimated to be a 
staggering 290 billion dollars, underscoring the dire need for viable treatment 
options 2.  However, recent drug failures have highlighted how much is still 
unknown about AD 3-18. What we do know is that a solution or cure for AD will 
likely require the continued research of the clinical, pathological, genetic and 
environmental factors that contribute to the underlying disease.  
 
1.1. Alzheimer’s Pathology:             
 It’s been 113 years since Alois Alzheimer published his landmark paper 
"Über eine eigenartige Erkrankung der Hirnrinde", a case description of a 55-
year-old German woman with an early age of dementia onset 19. Upon autopsy, 
Alzheimer took note of peculiar dense bundles of neurofibrils and “miliar foci” 
throughout the cortex, what we now know as neurofibrillary tangles (NFTs) and 
amyloid-beta (Aβ) plaques 19.  Though our techniques have become slightly more 
sophisticated, these pathological hallmarks of Alzheimer’s disease (the name 
was aptly given by the German psychologist, Emil Kraepelin) remain central to 
the diagnosis.   
Senile or neuritic plaque deposition follows a distinct distribution in AD 
described by Braak and Braak in 1991, following three stages, first appearing in 
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basal frontal, temporal and occipital cortex, then in isocortical association areas 
and finally depositing in primary isocortical areas 20,21. Though these plaques are 
associated with several abnormal components of the neuronal environment 
(including an abundance of microglia and astrocytes as well as paired helical 
filaments, PHFs), their primary core is the result of the accumulation of insoluble 
Aβ (largely Aβ42, Aβ40 to a lesser extent). Aβ40 and Aβ42 are released at the 
synapses of neurons after the proteolytic cleavage of amyloid precursor protein 
(APP) by β-secretase (BACE) and  -secretase 22. The accumulation of insoluble 
amyloid monomers into oligomers and plaques eventually leads to disruption of 
signaling at the synapses of cortical neurons, though it does not correlate 
temporally with cognitive decline 23.  Abnormal amyloid accumulation can 
precede cognitive symptoms by as much as 20 years and seems to plateau in 
early disease stages, making it an attractive candidate for early detection of 
disease pathological changes 24-26.   
The second pathological hallmark of AD, intracellular NFTs, are largely 
composed of PHFs which consist of hyperphosphorylated tau, a microtubule-
associated protein that loses its ability to stabilize the microtubule conformation 
when abnormally phosphorylated 27.  In human brains, there are six isoforms of 
tau generated through alternative splicing of exons 2, 3 and 10 in the 
microtubule-associated protein tau or MAPT gene. These six isoforms are 
typically categorized as either three or four repeat (3R or 4R, respectively), 
depending on whether they contain three or four carboxy-terminal repeat 
domains 28.  Tauopathies (neurodegenerative diseases involving the buildup of 
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tau protein) are often classified as 3R (Pick’s disease and some frontotemporal 
lobar degeneration MAPT mutations), 4R (progressive supranuclear palsy, 
corticobasal degeneration, globular glial tauopathies, argyrophilic grain disease 
and some frontotemporal lobar degeneration MAPT mutations) or 3R+4R 
(Alzheimer’s disease (sometimes referred to as a secondary tauopathy), primary 
age-related tauopathy and frontotemporal lobar degeneration MAPT mutations) 
depending on the isoforms that make up the PHFs 28. As with amyloid plaques, 
NFTs often follow a distinct pattern of deposition in AD, first restricted to the 
entorhinal cortex and hippocampus, then to limbic regions, and finally largely 
spanning isocortical regions 21,29.  However, contrary to amyloid, NFTs correlate 
well with the onset of clinical symptoms and severity of AD, which has prompted 
many to posit that targeting abnormal tau accumulation may be the most 
attractive target to stop or slow neurodegeneration 21,30,31.   
The combination of these pathologies may lead to downstream neuronal 
and synaptic loss, which can be seen as gross cortical atrophy, though the exact 
mechanisms to how this occurs are not well understood.  The neuropathological 
criteria for AD are dependent on an “ABC” score that is a summary of A. 
Aβ/amyloid plaque Thal phase score, B. NFT Braak score and C. Neuritic plaque 
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) score 32.  
The final score is determined to be either “Not”, “Low”, “Intermediate”, or “High” 
degree of AD neuropathologic change. 
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1.2. Clinical Considerations for Alzheimer’s disease: 
In 1984, a special National Institute of Neurological and Communicative 
Disorders and Stroke and Alzheimer’s Disease and Related Disorders (NINCDS-
ADRDA) workgroup met to discuss what were the original clinical guidelines for 
dementia due to Alzheimer’s disease 33.  Twenty-seven years later a similar 
meeting took place with several key additions to the original criteria 34.  First is 
the consideration of AD as a continuum, a slowly progressing disease with 
measurable stages that can be somewhat defined.  The workgroup was divided 
into three separate groups to recognize the three stages of the disease process.  
Those stages are the asymptomatic or preclinical stage, the prodromal or mild 
cognitive impairment (MCI) stage and finally the AD dementia stage (which was 
the sole focus of the previous workgroup in 1984). The second major addition to 
the diagnostic criteria is the recognition of biomarkers as a useful tool for 
clinicians.  The biomarkers considered are restricted to two categories indicative 
of AD pathophysiology 1) biomarkers of Aβ accumulation (abnormally high 
cortical retention of amyloid tracer as measured with positron emission 
tomography (PET) neuroimaging and/or low CSF Aβ42) and 2) biomarkers of 
neuronal degeneration or injury (abnormally high CSF tau, decreased 
fluorodeoxyglucose (FDG) PET uptake in the posterior cingulate gyrus or 
evidence of mesial temporal lobe atrophy on structural imaging) (more 
information on these biomarkers on pages 6 and 7) 34,35. 
The core clinical criteria for dementia are severe functional impairment 
and decline of activities of daily living which cannot be explained by delirium or 
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another major psychiatric disorder 35,36.  The impairment must be present in at 
least two cognitive domains from the list of memory, reasoning/handling of 
complex tasks, visuospatial, language or behavioral domains.  Probable AD 
dementia patients have an insidious onset of dementia with a gradual worsening 
of cognition whose most prominent symptoms are either amnestic (by far the 
most common presentation) or nonamnestic (affecting language, visuospatial or 
executive function with relative sparing of memory function).  This is a critical 
distinction from the previous criteria, which neglected the less common 
nonamnestic presenting AD dementias such as posterior cortical atrophy (PCA), 
logopenic primary progressive aphasia (PPA) and behavior variant AD.  As with 
the other stages, a crucial step involves ruling out other neurologic, psychiatric or 
general medical disorders that may impact cognition.  For the dementia stage, 
biomarkers are used to lend additional support to the clinical diagnosis of AD 
dementia.   
Since the 1984 inception of the diagnostic criteria, MCI has emerged as a 
legitimate clinical entity, though the diagnostic group remains largely 
heterogeneous in terms of pathological burden and/or etiology.  One of the key 
distinguishing factors between MCI and dementia is that MCI subjects, while 
cognitively impaired, generally maintain the independence of their day-to-day 
functional abilities. One of the main goals of the diagnostic criteria of 2011 was to 
help identify MCI who have cognitive symptoms most likely due to underlying AD 
pathology 37.  This determination is largely done, as within the dementia stage, by 
ruling out other likely systemic or brain diseases potentially responsible for 
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cognitive decline, such as vascular, Lewy body dementia, traumatic brain injury, 
hormonal disorders, etc.   Additional support may be given by the presence of a 
genetic mutation known to increase risk, such as those seen in mendelian forms 
of AD or APOE e4 allele carriers. The role of biomarkers in the MCI stage is to 
detect evidence of AD pathology to support the diagnosis.   
The preclinical stage of AD is considered still a research entity (i.e. not a 
clinical diagnosis) and is defined by normal cognition with evidence of 
Alzheimer’s pathology 38.  As mentioned previously, Alzheimer’s 
pathophysiological changes can begin as early as 20 years before cognitive 
symptoms arise, making the preclinical or asymptomatic stage the most attractive 
target to slow or even stop the progression of AD.  The caveat, of course, is 
finding specific and sensitive biomarkers to correctly identify these preclinical 
subjects.  
What is currently known about AD biomarkers is that they are dynamic 
throughout the disease progression and start first with measurable changes in 
amyloid 26.  This is first detectable through a reduction in CSF Aβ42 as more 
amyloid is sequestered into plaques (i.e. fewer free-floating Aβ42), followed by 
retention of cortical amyloid PET tracers. Amyloid typically reaches its peak near 
or just after cognitive symptoms are detectable, which is likely why amyloid does 
not correlate tightly with cognitive decline.  Amyloid PET tracers have been 
available since 2004 and currently there are three tracers which are FDA 
approved, [18F]Flortbetapir, [18F]Florbetaben and [18F]Flutemetamol, all which 
bind aggregated fibrillar forms of Aβ 39.  The advent of tau PET tracers adds an 
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additional detectable biomarker. Brain tau levels become abnormal sometime 
between amyloid accumulation and when CSF tau levels increase (as a result of 
cell death and subsequent release of intracellular tau into CSF).  Current 
understanding how of tau PET uptake correlates to postmortem data is limited, 
though early results indicate that the most widely used tracer, [18F]Flortaucipir, 
provides an accurate in vivo measure of 3 and 4 repeat NFT pathology 39,40.  As 
mentioned above, the abnormal accumulation of hyperphosphorylated tau into 
NFTs more closely correlates with cognitive symptoms than amyloidosis.  Finally, 
biomarkers of neuronal degeneration, such as raised CSF tau levels, reduction in 
FDG PET uptake in the posterior cingulate and mesial temporal hippocampal 
atrophy on structural imaging, are the final biomarkers to become abnormal 
before the beginning of cognitive decline.  FDG PET is used as an indirect 
measure of synapse loss, reflected by lower cellular intake of the tracer (also 
referred to as hypometabolism), whereas structural MR imaging provides 
excellent white/gray matter contrast that is crucial for tissue volumetric and 
thickness determinations.  While both of these measures are nonspecific to a 
disease process, specific spatial changes may indicate potential etiologies 39.  
A recent addition to the National Institute on Aging and Alzheimer’s 
Association (NIA-AA) clinical diagnostic criteria utilizes the known in vivo fluid 
and imaging biomarkers to define an AD classification research framework 
34,36,37,41.  Biomarkers are divided into three categories according to their 
hypothetical dynamic progression, amyloid (A), tau (T) and neurodegeneration 
(N), with a classifying positive (+) or negative (-) added, and the “+” designation 
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indicating that the abnormal threshold for a category has been crossed 41.  In this 
framework, amyloid-positive (A+) patients would fall within the Alzheimer’s 
continuum regardless of the other biomarkers.  The assumption made is that 
A+/T+/N+, A+/T+/N- or A+/T-/N- subjects are simply at various stages in the 
disease process.  Those who are A- are either considered normal (if T and N are 
negative) or have a non-AD pathologic change if there is abnormal tau and/or 
neurodegeneration 41.  The driving etiology behind non-AD pathologic change in 
AD phenocopies (clinically diagnosed AD without evidence of AD 
pathophysiology) is unknown, though they are likely a very heterogeneous group 
of pathologies (e.g., vascular, Lewy body, argyrophilic grain disease, 
frontotemporal dementia, hippocampal sclerosis, etc).  This is explored further in 
Chapter 2, where I investigate the ATN changes in across the prodromal-
dementia spectrum and discuss the presumed etiologies hypothesized from the 
observed tau and neurodegenerative patterns in amyloid-negative AD 
phenocopies or non-AD subjects.     
An additional clinical consideration is the age of symptom onset, which 
can, among other things, drastically impact the severity and speed of disease 
course 42-46.  An estimated 97% of all Alzheimer’s cases occur in the elderly 
population (65 and older, late-onset or LO), making age the single biggest risk 
factor for AD 2.  However, among the 3% of AD with symptom onset before 65, 
termed early-onset (EO), a vast majority are sporadic in origin 41,42.  EOAD 
presents several challenges to families and clinicians, not the least of which is 
the devastating effects it can have on adults who are still essential financial 
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earners for their families. From a clinical perspective, EOAD patients often have 
greater cognitive impairment, decline faster and are significantly more likely to 
have a nonamnestic presentation than LOAD 42-47.  The pathology echoes these 
differences between EO and LOAD, as EOAD typically present with far greater 
neuritic plaque and NFT burden 48-52. More recently, imaging biomarkers of AD 
have been used to recapitulate the pathological findings and show that in 
general, EOAD patients have a far greater tau burden as well as greater 
hypometabolism and atrophy 53-61.  The driving factor for this is likely a multitude 
of reasons.  At a surface level, rational arguments can be made that cognitive 
reserve, which in general is greater at younger ages, may require even greater 
pathologic burden to achieve the same level of cognitive deficit as in older 
patients. This means that a pathological comparison of relatively equally impaired 
EO to LOAD subjects would result in greater burden seen in the EO subjects.  At 
a deeper level, why this pathology occurs at such a young age and to such a 
great extent is unknown, though it likely has strong genetic and environmental 
components.  Currently, ongoing longitudinal observational studies, like the 
Longitudinal Early-Onset Alzheimer’s Disease Study or LEADS, the first large 
multisite early-onset study of its kind, are using clinical and neuropsychological 
testing, neuroimaging, fluid biomarkers and genetics to attempt to answer some 
of these questions.  In chapter 2, as mentioned above, I present a neuroimaging 
study of Alzheimer’s vs non-AD pathologic changes, which includes further 
dividing subjects by age of onset.  For this analysis, I subdivided AD groups into 
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EOAD and LOAD, while subdividing the non-AD groups into EOnonAD and 
LOnonAD.   
1.3. Genetics of Alzheimer’s disease: 
 AD has long been known to have a genetic component that was first 
identified in the small percentage of AD patients with dominantly inherited 
mutations, termed familial early-onset AD or Mendelian AD.  Patients with familial 
AD have mutations in one of three genes directly impacting amyloid production. 
The first gene is APP, which encodes a 770 amino acid transmembrane protein 
containing sites for several nonsynonymous mutations that increase the release 
of Aβ 62-65. The remaining two genes, presenilin 1 (PSEN1) and presenilin 2 
(PSEN2) encode proteins that are central to the function of the  -secretase 
complex 66,67.  Mutations found in these genes are believed to result in increased 
production of Aβ42, which is less soluble than other Aβ species (a full list of 
known mutations in APP, PSEN1 and PSEN2 can be found at 
https://www.alzforum.org/mutations) 68-72.   
In contrast to familial AD, sporadic AD is likely due to a combination of 
both genetic and environmental factors 2.  Over the last two decades, significant 
strides have been made towards better understanding the genetic risk factors 
contributing to this more genetically complex form, which has an estimated 
heritability of 70-80% 69,70.  Before the advent of large genome-wide association 
studies (GWAS), the apolipoprotein E (APOE) gene was the only highly accepted 
risk gene for sporadic AD.  This is because APOE has a large, dose-dependent 
risk (one copy of the e4 allele triples AD risk while two copies increase risk by 15) 
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73.  The impact of APOE e4 is so great that it has been called a moderately 
penetrant gene with semi-dominant inheritance 74.  It is important to note, though, 
that carrying a copy of the e4 allele is not determinate nor is sufficiently causative 
of Alzheimer’s disease.  It is also noteworthy that APOE explains less than half of 
the overall genetic risk for sporadic AD, which was not understood until the last 
decade, when GWAS became available.   
In an attempt to identify the remaining genetic risk, large-scale GWAS and 
meta-analysis of GWAS have identified genome-wide significant variants near 
over 20 genes 75-80.  Each of the discovered alleles contributes to only a small 
amount of risk, leading some to hypothesize that these genes may have an 
additive or synergistic effect when multiple risk variants are inherited together.  
Additionally, understanding the biological roles of the risk genes, regardless of 
whether or not they are considered to have direct functional consequences, is 
imperative to a better overall biological understanding of AD.  It is currently 
known that several risk genes are involved in pathways believed to be 
dysfunctional during the progression of AD, such as cholesterol metabolism 
(ABCA7, APOE, CLU, SORL1), immune response (ABCA7, CR1, CD33, CLU, 
EPHA1, MS4A6A) and endocytosis (BIN1, CD2AP, EPHA1, PICALM, SORL1) 81. 
Loci identified more recently are still being attributed to a dysfunctional 
Alzheimer’s process, though early work suggests potential consequences for 
CASS4(tau metabolism), CELF1(cytoskeleton/axon development), 
DSG2(cytoskeleton/axon development), FERMT2(tau metabolism), INPP5D(APP 
metabolism), MEF2C(endocytosis), NME8(cytoskeleton/axon development), 
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PTK2B(endocytosis), SLC24A4/RIN3(cholesterol/endocytosis) and 
ZCWPW1(epigenetics).   
One strategy used to associate gene to function is imaging genetics, 
which utilizes specific Alzheimer’s phenotypes.  This strategy has a distinct 
advantage over traditional gene to clinical diagnosis studies because imaging 
phenotypes are closer to biological changes due to genetics and remove much of 
the unwanted biomarker variation found with clinical Alzheimer’s disease. In 
chapters 3 and 4, I use imaging genetics to test associations between identified 
GWAS risk genes with a temporoparietal tau PET region of interest, posterior 
cingulate FDG PET SUVR and medial temporal lobe thickness.   Beyond testing 
for associations with genes across the full A/T/N biomarker spectrum, I 
investigate stage-specific genetic associations among cognitively normal (CN), 
mildly impaired (MCI) and subjects who have dementia (DEM).  This additional 
stage-stratified analysis was direct extension of my previous work on the 
associations of the top AD genetic hits with brain amyloidosis (reviewed in 
greater detail in Chapter 3).  Identifying variants associated with Alzheimer’s 
pathophysiological changes in the preclinical and prodromal stages may provide 
critical insight to previously unknown disease mechanisms, which could 
ultimately lead to the discovery of new therapeutic targets. 
 
1.4. Statement of Purpose: 
In general, the goals of this work were to use imaging biomarkers of AD to better 
understand the driving factors of the heterogeneity of clinically diagnosed AD in 
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regard to age of disease onset, biomarker abnormalities and genetic risk. More 
specifically, this work aimed to:   
1. Use imaging biomarkers of amyloid, tau and neurodegeneration to identify 
and both qualitatively and quantitatively characterize the differences 
between early vs. late and amyloid-positive vs. amyloid-negative clinically 
diagnosed Alzheimer’s subjects. 
2. Use imaging genetics to identify the genome-wide significant AD variants 
associated with neurodegeneration (FDG PET and MRI) and NFTs (tau 
PET).   
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Chapter 2. Neurodegenerative Changes in Early & Late-Onset Cognitive 
Impairment with and without Brain Amyloidosis 
2.1. Introduction: 
An estimated 5.8 million people in the United States are currently 
diagnosed with Alzheimer’s disease (AD) 2.   Even when rendered by dementia 
experts, the clinical diagnosis of AD shows only modest accuracy 82. Twenty-nine 
to 56% of clinically diagnosed AD patients are AD phenocopies that fail to show 
AD pathology upon postmortem examination 82. With the development of amyloid 
tracers for positron emission tomography (PET) we can now readily distinguish 
the true AD cases from the amyloid-negative AD phenocopies (nonAD).  
Ninety-seven percent of all AD cases have symptom onset at the age of 
65 or older and are classified as “late-onset” (LO), while the remaining 3% have 
symptom onset before the age of 65 and are termed “early-onset” (EO) 2,83,84 . 
Pathologically, patients who are younger at disease onset show greater 
pathological burden 48-52. Magnetic resonance imaging (MRI), 
[18F]Fluorodeoxyglucose (FDG) PET and [18F]Flortaucipir PET (tau PET) studies 
have shown that EO Alzheimer’s subjects (EOAD) have more extensive atrophy, 
hypometabolism and tau burden compared to LO Alzheimer’s subjects  (LOAD) 
53-57.  The more advanced pathologic burden in EOAD has been associated with 
more aggressive clinical course and is more likely to have an atypical 
presentation 42-45. To date the imaging biomarker profiles of early-onset nonAD 
(EOnonAD) have not been studied.  
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The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a multisite, 
longitudinal study that collects standardized imaging, genetic, clinical, and fluid 
biomarkers from clinically diagnosed amnestic mild cognitive impairment (MCI), 
clinically diagnosed Alzheimer’s dementia (DEM) and cognitively normal (CN) 
control subjects as a part of a global research effort to better understand LOAD. 
While the majority of ADNI subjects are older than 65 years, ADNI contains a 
sizeable cohort of amnestic EO MCI or dementia subjects (age of symptom onset 
<65 years). The addition of amyloid imaging in the ADNI-GO/2 funding stages 
allowed researchers to ascertain the amyloid PET status of all ADNI participants 
and provided researchers the opportunity to study the biomarker-validated AD 
and non-AD phenocopies in greater detail.  
In this study, my aim was to ascertain the extent and severity of tau and 
neurodegenerative pathology measured with tau PET, FDG PET and MRI in EO 
and LO ADNI cohorts stratified by amyloid status as follows: EOAD MCI and 
DEM (EOADMCI ; EOADDEM), EOnonAD MCI and DEM (EOnonADMCI; 
EOnonADDEM), LOAD MCI and DEM (LOADMCI; LOADDEM) and LOnonAD MCI 
and DEM (LOnonADMCI; LOnonADDEM).  I hypothesized that EOAD and 
EOnonAD subjects would have more severe neurodegeneration and greater tau 
burden relative to their LO counterparts, indicative of the greater disease burden 
likely required to have equivalent impairment to the significantly older LO group. I 
also hypothesized that nonAD cases would have a nonAD-like pattern of 
neurodegeneration. 
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2.2. Methods: 
Subjects 
Data used in the preparation of this article were obtained from the ADNI 
database (adni.loni.usc.edu). ADNI was launched in 2003 as a public-private 
partnership, led by Principal Investigator Michael W. Weiner, MD. The primary 
goal of ADNI has been to test whether serial MRI, PET, other biological markers, 
and clinical and neuropsychological assessments can be combined to accurately 
measure and predict the progression of MCI and Alzheimer’s dementia. ADNI 
has undergone three complete funding cycles to date: ADNI1, ADNI-GO and 
ADNI2 and is now in the ADNI3 cycle. ADNI-GO, ADNI2 and ADNI3 included 
[18F]Florbetapir amyloid PET imaging.  
The clinical and biomarker characteristics of the ADNI cohort have been 
previously published 85.  ADNI has enrolled clinically diagnosed CN, amnestic 
MCI and amnestic DEM subjects. Probable AD DEM diagnosis is based on the 
National Institute of Neurological and Communicative Disorders and Stroke and 
the AD and Related Disorders Association (NINCDS-ADRDA) criteria 33. 
Probable AD DEM subjects were 56 to 90 years old at enrollment, scored 
between 20 and 26 on the Mini-Mental State Examination (MMSE) 86 and 0.5–1 
on the Clinical Dementia Rating (CDR) global score 87. Subjects diagnosed as 
amnestic MCI ranged from 55 to 91 years old at enrollment, had no significant 
functional impairment, scored between 24 and 30 on the MMSE, had a global 
CDR of 0.5 (memory score ≥ 0.5), and impairment on Wechsler Memory Scale – 
Logical Memory II test 88. CN subjects had MMSE between 24 and 30, a global 
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CDR of 0 and did not meet criteria for MCI or DEM. Subjects were excluded due 
to inability to undergo MRI or if they had other neurological disorders, active 
depression, or history of psychiatric diagnosis, alcohol, or substance dependence 
within the past 2 years, less than 6 years of education or were not fluent in 
English or Spanish. The full list of inclusion/exclusion criteria may be accessed in 
the online ADNI protocol (http://www.adni-
info.org/Scientists/ADNIStudyProcedures.html). Written informed consent was 
obtained from all participants and the institutional review board (IRB) at all ADNI 
sites have reviewed and approved ADNI data collection protocol. 
For my analysis, I used 231 EO subjects with reported age of symptom 
onset ≤ 65 years from the ADNI database with available [18F]Florbetapir amyloid 
PET or CSF Aβ data (219 of the 231 received [18F]Florbetapir PET, the remaining 
12 had CSF Aβ data). One hundred seventy-three EO subjects met criteria for 
MCI; 58 for DEM. 60 MCI and 50 DEM were amyloid-positive (EOADMCI and 
EOADDEM) and 113 and 8, respectively, were amyloid-negative (EOnonADMCI and 
EOnonADDEM) based on previously validated [18F]Florbetapir global means 
standard uptake volume ratio (SUVR) cut-off of 1.17 89 or a CSF Aβ1-42 level < 
192 pg/ml 90. The subset with tau PET, [18F]Flortaucipir, included 10 EOADMCI, 7 
EOADDEM, 38 EOnonADMCI and 3 EOnonADDEM. 
LO subjects included had either [18F]Florbetapir amyloid PET (488/539 
subjects) or CSF Aβ data (51/539 subjects), and all had FDG PET and MR 
imaging.  Special care was taken to ensure that no LO diagnostic group was 
significantly more or less cognitively impaired than their EO counterpart 
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(measured by MMSE) by removing outlier subjects, resulting in 539 subjects. 
Three hundred sixty-seven met criteria for MCI and 172 for DEM. Two hundred 
sixteen LO MCI and 148 LO DEM were amyloid-positive (LOADMCI and 
LOADDEM), while 151 LO MCI and 24 LO DEM were amyloid-negative 
(LOnonADMCI; LOnonADDEM). The subset with tau PET included 53 LOADMCI, 27 
LOADDEM, 51 LOnonADMCI and 2 LOnonADDEM. Due to the low numbers of EO 
and LO nonADDEM subjects with [18F]Flortaucipir scans (3 and 2, respectively) 
they were grouped together with the EO and LO nonADMCI, resulting in 41 
EOnonAD and 53 LOnonAD subjects in the tau comparisons.   
Since EO and LO groups cannot be directly compared because 
neurodegenerative changes associated with aging could inadvertently confound 
the results, I conducted two sets of analyses. I first compared each EO and LO 
group to the same CN comparison group comprised of the 291 amyloid-negative 
(SUVR<1.17) CN subjects within the age range of 55 to 90 years old. This 
comparison allowed for a straightforward interpretation of the effect sizes as a 
measure of disease impact. Next, I repeated the analyses comparing the LO and 
EO groups to only the older (N=146) and younger half (N=145) of CN, 
respectively. 
MRI and PET acquisition and analyses 
ADNI MRI and PET acquisition and preprocessing protocols can be found 
at www.adni-info.org. The MRI data acquisition and preprocessing have been 
previously described elsewhere 33. I downloaded preprocessed MRI data from 
LONI IDA (https://ida.loni.usc.edu). Scans were spatially warped to Montreal 
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Neurological Institute (MNI) space and segmented into gray matter (GM), white 
matter, and CSF components using voxel-based morphometry (VBM) in 
Statistical Parametric Mapping version 12 (SPM12), as described previously 91. 
GM maps were normalized and smoothed using 10 mm full-width half maximum 
(FWHM) Gaussian kernel, which yielded gray matter density (GMD) data. 
Intracranial volume (ICV) was also calculated using FreeSurfer version 5.1.   
PET scanners across sites were held to rigorous qualifications, calibration, 
and normalization standards as described in detail elsewhere 87.  I downloaded 
preprocessed amyloid, FDG PET and tau PET data from LONI IDA 
(https://ida.loni.usc.edu). The scans were already averaged, aligned to standard 
space, re-sampled to a standard image and voxel size (2mm × 2mm × 2mm), 
and smoothed to a uniform resolution as previously described 92.  I aligned the 
images to the corresponding MRI scan from the same visit and normalized them 
to MNI space using parameters obtained from the MRI segmentation using 
SPM12. PET scans were intensity normalized to mean pons uptake for FDG, 
whole cerebellum for amyloid and cerebellar crus for tau PET, resulting in whole 
brain SUVR images as previously described 93,94.   To assign subjects into 
groups by amyloid status, I used an amyloid PET cutoff of SUVR ≥ 1.17 or CSF 
Aβ1-42 level < 192 pg/ml  89,90.  
Statistical Analyses 
Clinical and Demographic Analyses: 
The statistical distribution of clinical and demographic characteristics (age, 
education, global CDR, MMSE, and amyloid PET mean global SUVR) were 
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analyzed in SPSS version 24.2 using one-way ANOVA. ANOVA p-values are 
listed in the tables and Bonferroni-corrected multiple comparisons p-values are 
listed in the results text. APOE4 genotype and sex frequency comparisons were 
done using a chi-square test with two-sided p-values. The alpha value for all 
comparisons was p<0.05.  
Parametric Mapping: 
I used voxel-wise linear regression models in SPM12 to study the extent 
and severity of neurodegeneration and tau burden in EO and LO AD and nonAD 
groups relative to CN while controlling for age, sex and education.  Additionally, 
in the MRI analyses, I covaried for MRI field strength (1.5T vs. 3T) and ICV.  
Family-wise error (FWE) cluster-level correction was applied to correct for 
multiple comparisons with a significance threshold of p<0.01.  Because side-by-
side interpretation of significance maps generated with unequal sample sizes can 
be misleading, I also derived β-coefficient maps to demonstrate the effect sizes 
in each comparison, which are visualized using the MRIcrogl version 2.1 
software. 
 
2.3. Results: 
AD analyses 
Demographic comparisons: 
The demographic, neuropsychological, and amyloid burden comparisons 
of the amyloid positive diagnostic groups relative to CN are shown in Table 1. 
The CN were significantly older than the EO and significantly younger than the 
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LO subjects (p<0.001, both). The CN subjects had significantly fewer APOE4 
carriers compared to all other groups (p<0.001, all). The age and APOE4 effects 
remained when the data were split into younger and older subgroups (Table 2). 
As expected, the EOADMCI and EOADDEM subjects were significantly 
younger compared to the LOADMCI and LOADDEM groups (p<0.001, Table 3, top). 
Compared to EOADMCI, LOADMCI had significantly fewer years of education 
(p=0.021). The EOADDEM and LOADDEM groups showed similar education. Both 
EOAD groups had a significantly higher percentage of APOE e4 homozygotes 
compared to LOAD subjects (MCI p=0.004, DEM p=0.022). There were no 
significant differences in global [18F]Florbetapir SUVR, global CDR or MMSE 
between the EO and LOAD groups. 
Regional amyloid comparisons between the AD subjects showed a 
significant difference (p=0.044) in parietal cortices and significant (p=0.048) 
difference in temporal amyloid SUVR between EOADMCI and EOADDEM (Table 4).  
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Table 1. EOAD and LOAD demographic comparisons to CN. The comparisons 
were done using ANOVA and chi-square tests with two-sided p-values. The 
Bonferroni-corrected pairwise differences are discussed in the Results section. 
Significant p-values (<0.05) are bolded.  
*Significantly different than CN group at p<0.05 
**Significantly different than CN group at p<0.01 
***Significantly different than CN group at p<0.001 
 
  
Variable 
 
CN  
(N=291) 
 
 
EOADMCI 
(N=60)  
EOADDEM 
(N=50) p-value 
 
LOADMCI 
(N=216) 
 
LOADDEM 
(N=148) p-value 
Age, years, 
Mean (SD) 74.3 (6.4) 65.4 (6.0)*** 64.7 (6.3)*** <0.001 76.4 (5.8)*** 
78.3 
(5.9)*** <0.001 
Sex, 
Male % 52.2 46.7 44.0 0.461 60.2 58.8 0.174 
Education, 
years, Mean 
(SD) 
16.7 (2.6) 16.7 (2.8) 15.6 (2.4)** 0.022 15.8 (2.8)*** 15.4 (3.0)*** <0.001 
% APOE e4, 
0/1/2 alleles 77/22/1 18/52/30*** 26/38/36*** <0.001 34/52/14*** 26/56/18*** <0.001 
Global CDR, 
Mean (SD) 
0.02 
(0.09) 
0.50 
(0.00)*** 
0.87 
(0.33)*** <0.001 0.50 (0.16)*** 
0.84 
(0.36)*** <0.001 
MMSE, 
Mean (SD) 29.0 (1.3) 27.8 (1.8)*** 22.5 (3.3)*** <0.001 27.4 (1.9)*** 
23.0 
(2.8)*** <0.001 
Global 
Cortical 
[18F]Florbet
apir SUVR, 
Mean (SD) 
1.03 
(0.06) 
1.41 
(0.15)*** 
1.48 
(0.13)*** <0.001 1.43 (0.17)*** 
1.47 
(0.16)*** <0.001 
Tau Scans, 
N 126 10 7 N/A 53 27 N/A 
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Table 2.  EOAD and LOAD demographic comparisons to the young and old CN 
groups, resp. The comparisons were done using ANOVA and chi-square tests 
with two-sided p-values. The Bonferroni-corrected pairwise differences are 
discussed in the Results section. Significant p-values (<0.05) are bolded.  
*Significantly different than CN group at p<0.05 
**Significantly different than CN group at p<0.01 
***Significantly different than CN group at p<0.001 
  
Variable 
 
 Young 
CN 
(N=145) 
 
 
EOADMCI 
(N=60)  
EOADDEM 
(N=50) 
p-
value 
 
Old CN  
(N=146) 
 
LOADMCI 
(N=216) 
LOADDEM 
(N=148) 
p-
value 
Age, 
years, 
Mean (SD) 
69.1 (3.3) 65.4 (6.0)*** 
64.7 
(6.3)*** 
<0.00
1 79.4 (4.3) 
76.4 
(5.8)*** 78.3 (5.9) 
<0.00
1 
Sex, 
Male % 50.3 46.7 44.0 0.713 54.1 60.2 58.8 0.505 
Education
, years, 
Mean (SD) 
16.7 (2.5) 16.7 (2.8) 15.6 (2.4)** 0.027 16.7 (2.7) 15.8 (2.8)** 15.4 (3.0)*** 
<0.00
1 
% APOE 
e4, 0/1/2 
alleles 
74/25/1 18/52/30*** 26/38/36*** <0.001 80/18/2 34/52/14*** 26/56/18*** 
<0.00
1 
Global 
CDR, 
Mean (SD) 
0.02 
(0.10) 
0.50 
(0.00)*** 
0.87 
(0.33)*** 
<0.00
1 
0.01 
(0.07) 
0.50 
(0.16)*** 
0.84 
(0.36)*** 
<0.00
1 
MMSE, 
Mean (SD) 29.1 (1.1) 
27.8 
(1.8)*** 
22.5 
(3.3)*** 
<0.00
1 28.8 (1.4) 
27.4 
(1.9)*** 
23.0 
(2.8)*** 
<0.00
1 
Global 
Cortical 
[18F]Florbe
tapir 
SUVR, 
Mean (SD) 
1.04 
(0.06) 
1.41 
(0.15)*** 
1.48 
(0.13)*** 
<0.00
1 
1.01 
(0.06) 
1.43 
(0.17)*** 
1.47 
(0.16)*** 
<0.00
1 
Tau 
Scans, N 55 10 7  71 53 27  
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Table 3. EO vs. LO demographic comparisons. The comparisons were done 
using ANOVA and chi-square tests with two-sided p-values. Significant p-values 
(<0.05) are bolded.  In addition, pairwise comparisons of MCI to DEM for each 
group are displayed using the following symbols to denote a significant 
difference. 
*Significantly different between MCI and DEM at p<0.05 
**Significantly different between MCI and DEM at p<0.01 
***Significantly different between MCI and DEM at p<0.001 
 
Diagnostic group (N) EOADMCI (N=60) 
LOADMCI 
 (N=216) p-value 
EOnonADMCI 
 (N=113) 
LOnonADMCI 
 (N=151) p-value 
Age, years, Mean (SD) 65.4 (6.0) 76.4 (5.8)** <0.001 65.5 (5.8) 77.6 (6.2) <0.001 
Sex, Male % 46.7 60.2 0.065 50.4 59.6* 0.138 
Education, years, Mean (SD) 16.7 (2.8)* 15.8 (2.8) 0.021 16.2 (2.5) 16.3 (2.5) 0.848 
% APOE e4, 0/1/2 alleles 18/52/30 34/52/14 0.004 68/30/2 86/13/2 0.005 
Global CDR, Mean (SD) 0.50 (0.00)*** 0.50 (0.16)*** 0.823 0.46 (0.17)*** 0.48 (0.11)*** 0.167 
MMSE, Mean (SD) 27.8 (1.8)*** 27.4 (1.9)*** 0.229 28.6 (1.5)*** 28.4 (1.6)*** 0.175 
Global Cortical 
[18F]Florbetapir SUVR, 
Mean (SD) 
1.41 (0.15)* 1.43 (0.17)* 0.315 1.03 (0.08) 1.01 (0.09) 0.115 
Tau scans, N 10 53 N/A 38 51 N/A 
Diagnostic group (N) EOADDEM  (N=50) 
LOADDEM 
 (N=148) p-value 
EOnonADDEM 
 (N=8) 
LOnonADDEM 
 (N=24) p-value 
Age, years, Mean (SD) 64.7 (6.3) 78.3 (5.9)** <0.001 66.3 (5.8) 79.4 (5.8) <0.001 
Sex, Male % 44.0 58.8 0.069 50.0 83.3* 0.059 
Education, years, Mean (SD) 15.6 (2.4)* 15.4 (3.0) 0.668 15.6 (3.5) 15.6 (3.0) 1.000 
% APOE e4, 0/1/2 alleles 26/38/36 26/56/18 0.022 71/14/14 83/13/4 0.642 
Global CDR, Mean (SD) 0.87 (0.33)*** 0.84 (0.36)*** 0.579 0.69 (0.26)*** 0.83 (0.24)*** 0.155 
MMSE, Mean (SD) 22.5 (3.3)*** 23.0 (2.8)*** 0.283 23.0 (2.4)*** 23.6 (1.9)*** 0.453 
Global Cortical 
[18F]Florbetapir SUVR, 
Mean (SD) 
1.48 (0.13)* 1.47 (0.16)* 0.616 1.04 (0.08) 1.01 (0.10) 0.485 
Tau scans, N 7 27 N/A 3 2 N/A 
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Table 4. Regional amyloid PET ([18F]Florbetapir) comparisons between amyloid 
positive subjects for frontal, cingulate, parietal and temporal cortices. *Temporal 
SUVR was significantly different (p=0.048) between EOADMCI and EOADDEM 
subjects 
  
Amyloid 
Regions EOADMCI EOADDEM LOADMCI LOADDEM 
ANOVA 
p-values 
Frontal 
SUVR 1.38 (0.18) 1.47 (0.17) 1.41 (0.17) 1.43 (0.17) 0.083 
Cingulate 
SUVR 1.47 (0.19) 1.55 (0.15) 1.50 (0.18) 1.53 (0.18) 0.112 
Parietal 
SUVR 1.38 (0.19) 1.47 (0.15) 1.40 (0.17) 1.44 (0.17) 0.044 
Temporal 
SUVR 
1.27 
(0.18)* 
1.37 
(0.17)* 1.30 (0.16) 1.33 (0.16) 0.023 
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Imaging comparisons: 
The FWE cluster-level corrected maps of the MRI, FDG PET and tau PET 
comparisons of EOAD and LOAD spectrum individuals to CN are shown in 
Figure 1. The same analyses limited to only subjects with tau PET scans are 
shown in Figure 2 while Figure 3 displays comparisons of EOAD and LOAD to 
younger and older CN subgroups, resp. The pattern of neurodegeneration and 
tau deposition seen in Figure 1 and Figures 2 and 3 are very similar discounting 
the probability of exaggerated age or selection bias.  
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Figure 1.  MRI (top), FDG PET (middle), tau PET (bottom) comparisons between 
the AD groups and CN. The significance maps show p<0.05 thresholded FWE 
cluster-level corrected results of EOADMCI (N=60), EOADDEM (N=50), LOADMCI 
(N=216) and LOADDEM (N=148) vs. CN (N=291). The results displayed here are 
for all subjects with available scans in each modality.  
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Figure 2.  MRI (top) and FDG PET (bottom) comparisons between the AD and 
CN groups restricted to only subjects with available tau PET scans. The 
significance maps show p<0.05 thresholded FWE cluster-level corrected results. 
of EOADMCI (N=10), EOADDEM (N=7), LOADMCI (N=53) and LOADDEM (N=27) vs. 
CN (N=126) 
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Figure 3.   MRI (top), FDG PET (middle), tau PET (bottom) comparisons 
between young CN and EOnonAD and old CN and LOnonAD groups. The 
significance maps show p<0.05 thresholded FWE cluster-level corrected results 
of EOADMCI (N=60) and EOADDEM (N=50) vs young CN (N=145), LOADMCI 
(N=216) and LOADDEM (N=148) vs. old CN (N=146).  
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MRI (Figure 1, top panel) 
The EOADMCI group showed two significant clusters of atrophy in the left 
and right medial and lateral temporal and left frontal cortices relative to the CN 
group (left cluster: cluster size k=45797, cluster pFWE<0.001; right cluster: 
k=20760, cluster pFWE=0.003). Compared to the CN group, the LOADMCI cohort 
showed significant atrophy of the bilateral medial and lateral temporal, 
temporoparietal, insular, occipital and frontal regions (single cluster k=688646, 
cluster pFWE<0.001). The EOADMCI group visually showed a larger effect size (i.e., 
more severe atrophy) than LOADMCI in overlapping regions (see β-coefficient 
maps in Figure 1, top panel).  
Both EOADDEM and LOADDEM showed extensive atrophy throughout the 
brain compared to CN (single clusters, kEO=1541575, kLO=1503763, cluster 
pFWE<0.001 for both). The significance and β-coefficient maps show a stronger 
effect size (i.e., more severe atrophy) in the EOADDEM than the LOADDEM group 
(see β-coefficient maps in Figure 1, top panel). 
 
FDG PET (Figure 1, middle panel) 
Compared to CN, EOADMCI showed a significant hypometabolic cluster in 
bilateral medial and lateral temporal and lateral, temporoparietal cortices 
(k=32246, cluster pFWE<0.001). Additionally, there was a small cluster of 
hypometabolism in bilateral dorsolateral prefrontal cortex (k=3396, cluster 
pFWE<0.001). LOADMCI subjects showed hypometabolism of the bilateral inferior 
temporal, medial and lateral temporal and parietal cortices as well as bilateral 
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frontal cortex (single cluster, k=94307, cluster pFWE<0.001, Figure 1, middle 
panel).  
Both the EOADDEM and LOADDEM groups showed extensive 
hypometabolism relative to CN in bilateral parietal, temporal, and frontal lobes, 
as well as insular and cingulate cortices (single clusters, kEO=148701, 
kLO=185998, cluster pFWE<0.001 for both). As with the MRI analysis, the 
EOADDEM group showed a stronger effect size (i.e., more severe 
hypometabolism) than the LOADDEM group (see β-coefficient maps in Figure 1, 
middle panel). 
 
Tau PET (Figure 1, bottom panel) 
These analyses were limited to the subset of individuals with available tau 
PET imaging. Compared to the CN group, the EOADMCI group had a significant 
cluster of tau binding covering temporal, parietal, parietooccipital and right frontal 
cortices (k=74981, cluster pFWE<0.001).  An additional significant cluster of tau 
binding was present in the left prefrontal cortex (k=9800, cluster pFWE<0.001). 
The LOADMCI cohort showed tau deposition in a similar pattern (single cluster, 
k=96885, cluster pFWE<0.001). The beta coefficient maps demonstrated greater 
tau burden in EOADMCI compared to LOADMCI (see β-coefficient maps in Figure 
1, bottom panel). 
EOADDEM showed tau binding in all cortical regions save for the primary 
sensorimotor and visual cortices (single cluster, k=157966, cluster pFWE<0.001). 
LOADDEM showed two significant clusters of tau binding – one in the posterior 
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association cortices (k=67260, cluster pFWE<0.001) and a smaller one in the 
bilateral prefrontal cortices (k=4931, cluster pFWE<0.001). The β-coefficient maps 
show much more severe and extensive tau deposition in EOADDEM compared to 
LOADDEM (see β-coefficient maps in Figure 1, bottom panel). 
 
NonAD analyses: 
Demographic comparisons: 
Direct comparisons of CN to EOnonADMCI, LOnonADMCI, EOnonADDEM 
and LOnonADDEM showed the expected significant difference in age, global CDR 
and MMSE (p<0.001, Table 5). Compared to CN, LOnonADDEM had a greater 
proportion of men (p=0.003) and lower education (p=0.044). Even when split in 
younger and older subgroups, the age differences between CN and the 
respective disease groups remained significant (Table 6). 
 By definition, EOnonADMCI and EOnonADDEM were significantly younger 
than the corresponding LOnonAD groups (p<0.001). The EOnonADMCI group had 
a higher proportion of APOE e4 carriers compared to the LOnonADMCI group 
(p=0.005). There were no significant differences in sex, education, global CDR, 
MMSE or global [18F]Florbetapir SUVR between the groups. 
 A closer look into regional amyloid differences among nonAD subjects 
revealed significant differences between LOnonADMCI and LOnonADDEM parietal 
amyloid SUVR (p=0.045, Table 7). No other region was significantly different 
across nonAD groups.  
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Table 5. EOnonAD and LOnonAD demographic comparisons to CN. The 
comparisons were done using ANOVA and chi-square tests with two-sided p-
values. The Bonferroni-corrected pairwise differences are discussed in the 
Results section. Significant p-values (<0.05) are bolded. 
*Significantly different than CN group at p<0.05 
**Significantly different than CN group at p<0.01 
***Significantly different than CN group at p<0.001 
 
  
Variable 
 
CN  
(N=291) 
 
EOnonADMCI 
(N=113) 
EOnonADDEM 
(N=8) p-value 
LOnonADMCI 
(N=151) 
LOnonADDE
M(N=24) p-value 
Age, years, 
Mean (SD) 74.3 (6.4) 65.5 (5.8)*** 66.3 (5.8)*** <0.001 77.6 (6.2)*** 79.4 (5.8)*** <0.001 
Sex, 
Male % 52.2 50.4 50.0 0.944 59.6 83.3** 0.008 
Education, 
years, Mean 
(SD) 
16.7 (2.6) 16.2 (2.5) 15.6 (3.5) 0.095 16.3 (2.5) 15.6 (3.0)* 0.037 
% APOE e4, 
0/1/2 alleles 77/22/1 68/30/2 71/14/14 0.028 86/13/2* 83/13/4 0.173 
Global CDR, 
Mean (SD) 0.02 (0.09) 0.46 (0.17)*** 0.69 (0.26)*** <0.001 0.48 (0.11)*** 
0.83 
(0.24)*** <0.001 
MMSE, 
Mean (SD) 29.0 (1.3) 28.6 (1.5)* 23.0 (2.4)*** <0.001 28.4 (1.6)*** 23.6 (1.9)*** <0.001 
Global 
Cortical 
[18F]Florbeta
pir SUVR, 
Mean (SD) 
1.03 (0.06) 1.03 (0.08) 1.04 (0.08) 0.214 1.01 (0.09) 1.01 (0.10) 0.160 
Tau scans, N 126 38 3 N/A 51 2 N/A 
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Table 6.  EOnonAD and LOnonAD demographic comparisons to the young and 
old CN groups, resp. The comparisons were done using ANOVA and chi-square 
tests with two-sided p-values. The Bonferroni-corrected pairwise differences are 
discussed in the Results section. Significant p-values (<0.05) are bolded. 
*Significantly different than CN group at p<0.05 
**Significantly different than CN group at p<0.01 
***Significantly different than CN group at p<0.001 
  
Variable 
 
Young CN 
(N=145) 
 
 
EOnonADMCI 
(N=113)  
EOnonADDE
M 
(N=8) 
p-
value 
 
Old CN  
(N=146) 
 
LOnonADMCI 
(N=151) 
LOnonADDE
M 
(N=24) 
p-
value 
Age, years, 
Mean (SD) 69.1 (3.3) 65.5 (5.8)*** 66.3 (5.8)* 
<0.00
1 79.4 (4.3) 77.6 (6.2)** 79.4 (5.8) 0.010 
Sex, 
Male % 50.3 50.4 50.0 0.990 54.1 59.6 83.3** 0.026 
Education, 
years, Mean 
(SD) 
16.7 (2.5) 16.2 (2.5) 15.6 (3.5) 0.138 16.7 (2.7) 16.3 (2.5) 15.6 (3.0) 0.078 
% APOE e4, 
0/1/2 alleles 74/25/1 68/30/2 71/14/14* 0.066 80/18/2 86/13/2 83/13/4 0.630 
Global CDR, 
Mean (SD) 0.02 (0.10) 0.46 (0.17)*** 0.69 (0.26)*** 
<0.00
1 0.01 (0.07) 0.48 (0.11)*** 0.83 (0.24)*** <0.001 
MMSE, 
Mean (SD) 29.1 (1.1) 28.6 (1.5)** 23.0 (2.4)*** 
<0.00
1 28.8 (1.4) 28.4 (1.6)** 23.6 (1.9)*** <0.001 
Global 
Cortical 
[18F]Florbet
apir SUVR, 
Mean (SD) 
1.04 (0.06) 1.03 (0.08) 1.04 (0.08) 0.749 1.01 (0.06) 1.01 (0.09) 1.01 (0.10) 0.986 
Tau Scans, 
N 55 38 3  71 51 2  
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Table 7. Regional amyloid PET ([18F]Florbetapir) comparisons between amyloid 
negative subjects for frontal, cingulate, parietal and temporal cortices.  
  
Amyloid 
Regions CN EOnonADMCI EOnonADDEM 
LOnonAD-
MCI LOnonADDEM 
ANOVA 
p-
values 
Frontal 
SUVR 
1.01 
(0.07) 1.01 (0.06) 1.05 (0.08) 1.00 (0.08) 0.99 (0.12) 0.304 
Cingulate 
SUVR 
1.11 
(0.08) 1.11 (0.09) 1.16 (0.07) 1.09 (0.09) 1.09 (0.11) 0.187 
Parietal 
SUVR 
1.02 
(0.07) 1.02 (0.07) 1.06 (0.06) 1.01 (0.08) 1.02 (0.10) 0.394 
Temporal 
SUVR 
0.96 
(0.06) 0.95 (0.06) 0.99 (0.05) 0.95 (0.07) 1.01 (0.08) 0.112 
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Imaging comparisons: 
The FWE cluster-level corrected MRI, FDG PET and tau PET comparison 
maps of the nonAD groups to CN are shown in Figure 4. The same analyses 
limited to only subjects with tau PET scans are shown in Figure 5, while Figure 
6 displays comparisons of EOnonAD and LOnonAD to younger and older CN 
subgroups, resp. The pattern of neurodegeneration and tau deposition seen in 
Figure 16 is largely identical to the one in Figure 4, with the exception of 
emerging tau deposition in bilateral frontal and right parietal lobes in EOnonAD 
when compared to the young CN.  
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Figure 4. MRI (top), FDG PET (middle), tau PET (bottom) comparisons between 
the nonAD groups and CN. The significance maps show p<0.05 thresholded 
FWE cluster-level corrected results of EOnonADMCI (N=113), EOnonADDEM 
(N=8), LOnonADMCI (N=151) and LOnonADDEM (N=24) vs. CN (N=291).  The 
results displayed here are for all subjects with available scans in each modality. 
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Figure 5.   MRI (top) and FDG PET (bottom) comparisons between the nonAD 
and CN groups restricted to only subjects with available tau PET scans. The 
significance maps show p<0.05 thresholded FWE cluster-level corrected results 
of EOnonADMCI (N=38), EOnonADDEM (N=3), LOnonADMCI (N=51) and 
LOnonADDEM (N=2) vs. CN (N=126).  
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Figure 6.   MRI (top), FDG PET (middle), tau PET (bottom) comparisons 
between young CN and EOAD and old CN and LOAD groups. The significance 
maps show p<0.05 thresholded FWE cluster-level corrected results of 
EOnonADMCI (N=113) and EOnonADDEM (N=8) vs young CN (N=145), 
LOnonADMCI (N=151) and LOnonADDEM (N=24) vs. old CN (N=146). 
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MRI (Figure 4, top panel) 
EOnonAD showed no significant atrophy compared to the CN group.  
LOnonADMCI showed extensive atrophy in the bilateral medial and lateral 
temporal, temporoparietal, parietooccipital and frontal cortices (single cluster, 
k=569219, cluster pFWE<0.001). LOnonADDEM had similarly widespread atrophy 
showing two significant clusters – one in bilateral temporoparietal and frontal 
cortices (k=602716, cluster pFWE <0.001) and another in the cerebellum 
(k=13494, cluster pFWE=0.020). The largest effect size was observed in 
LOnonADDEM with greatest predilection for the medial and inferior temporal lobes 
(see β-coefficient maps in Figure 4, top panel).  
 
FDG PET (Figure 4, middle panel) 
Compared to CN, EOnonADMCI showed no significant hypometabolism, 
while the EOnonADDEM group showed three significant clusters in left and right 
temporoparietal (left: k=15114, cluster pFWE<0.001; right: k=6104, cluster 
pFWE<0.001) and bilateral frontal cortices (single cluster, k=3002, cluster 
pFWE<0.001). LOnonADMCI showed a significant cluster of hypometabolism in 
bilateral temporal and prefrontal cortices (k=24278, cluster pFWE<0.001). A similar 
fronto-temporal pattern of hypometabolism was also observed in LOnonADDEM; 
however, it also extended to the parietal lobes (single cluster, k=78550, cluster 
pFWE<0.001). 
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Tau PET (Figure 4, bottom panel) 
Due to the small sample sizes, the EOnonAD and LOnonAD groups were 
not split by disease stage.  There were no significant tau binding in either 
EOnonAD or LOnonAD. As mentioned above, EOnonAD showed tau deposition 
in bilateral frontal (single cluster, k=7215, cluster pFWE<0.001) and right parietal 
lobes (single cluster, k=4664, cluster pFWE<0.001) when compared to young CN 
only (Figure 4). 
  
2.4. Discussion: 
The current study aimed to map neurofibrillary, structural and metabolic 
differences between EO and LO MCI and DEM subjects stratified by amyloid 
positivity.  As expected I found that EOADMCI and EOADDEM subjects show more 
severe neurodegeneration and greater tau deposition compared to LOADMCI and 
LOADDEM, respectively, a finding that is consistent with previous imaging reports 
45,48-54,57, and with the fact that EO individuals have a much more aggressive 
disease course 42,45.  
The availability of amyloid PET imaging or CSF Aβ measurements allowed 
me to identify nonAD cases that were enrolled as Alzheimer’s phenocopies. 
While I failed to find significant neurodegeneration in EOnonADMCI, I observed 
significant hypometabolism in EOnonADDEM in the absence of significant atrophy, 
a finding that could be indicative of synaptic dysfunction before cellular loss.  The 
lack of findings, particularly in the EOnonADMCI subjects, where the 
neurodegenerative changes are likely subtle, may be due to the inability to 
properly account for age-related degeneration (despite covarying for age during 
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the analysis) when comparing directly to the CN subjects who are significantly 
older. In the EOnonADDEM subjects, the lack of visible atrophy on statistical maps 
may be due to a relatively small sample size, as the beta-coefficient maps 
indicate a pattern of neurodegeneration similar to that seen in the FDG PET 
analysis.  Furthermore, the EOnonADDEM subjects may be a heterogeneous 
group of multiple etiologies, making detection of significant clusters of atrophy 
difficult.   
LOnonAD cases showed pronounced atrophy and hypometabolism with 
greatest predilection for the temporal and frontal lobes. This pattern of 
neurodegeneration has been reported in primary age-related tauopathy (PART) 
and hippocampal sclerosis with TAR-DNA binding protein 43 (TDP-43) inclusions 
(HS-TDP-43) 95,96. Both conditions are highly prevalent among the elderly with 
and without cognitive deficit 95,96, however, of these two, HS-TDP-43 (also known 
as limbic-predominant age-related TDP-43 encephalopathy (LATE)97) is the more 
likely etiology due to the lack of tau binding in the medial temporal lobes which is 
expected in PART.  It is worth noting that though [18F]Flortaucipir binds well to 
mature tangles in 3R+4R tauopathies, such as in AD and PART 98,99, further post 
mortem studies are needed to say with confidence which tauopathy tau variants 
can reliably be bound with Flortaucipir.  
The hypometabolic pattern I observed in LOnonAD fits well with previous 
pathologic and imaging reports of LATE. TDP-43 inclusions and neurite deposits 
first appear in the hippocampal dentate granule cells, subiculum and the 
amygdala 96,100,101. In more advanced stages, TDP-43 pathology is also found in 
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frontal and temporal neocortex 96,100,101.  TDP-43 pathology is extremely 
prevalent among cognitively impaired elderly and is the stand-alone pathology in 
4.2% of these cases 96,100,102,103. 86% of TDP-43 positive cases have HS-TDP-43 
96,104-106. HS-TDP-43 oftentimes show episodic and semantic memory 
dysfunction, explaining how they could easily be diagnosed clinically with AD 107. 
Individuals with HS-TDP-43 have greater hippocampal atrophy and greater 
cognitive impairment than those with HS without TDP-43 100,101,104.  Additional 
support for my hypothesis that the LOnonAD subjects likely harbor HS-TDP-43 
are the recent reports that HS-TDP-43 cases show hypometabolic changes in the 
medial and lateral temporal, posterior and middle cingulate, precuneus, and 
prefrontal cortex, similar to the FDG PET pattern I observed in LOnonADMCI and 
LOnonADDEM 108. Similar hypometabolic and atrophy patterns involving medial 
and lateral temporal and prefrontal cortices were recently reported in two 
additional clinic-pathologic studies 109,110.   
An additional possibility is that some LOnonAD subjects may suffer from 
behavioral variant frontotemporal dementia (bvFTD).  However, this is less likely 
given the mean age of the LOnonAD cohorts (77.6 and 79.4 years, respectively) 
and their amnestic predominant presentation at enrollment as required by ADNI 
(see http://www.adni-info.org/Scientists/ADNIStudyProcedures.html). It is worth 
noting, however, that in rare cases (10% of pathologically confirmed bvFTD 
cases), patients presented with primarily amnestic symptoms and some studies 
have even reported as much as 25% of pathologically confirmed FTLD cases to 
have a disease onset after the age of 65 111,112.   
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2.5. Strengths and Limitations: 
Several strengths and limitations of my study should be noted. One of the 
strengths is the relatively large sample size of EO subjects available through 
ADNI.  Additionally, ADNI employs meticulously standardized clinical and 
imaging data collection, which is routinely subjected to quality control. One of the 
limitations of my analyses is the cross-sectional design and the measurement of 
atrophy, which has a temporal component. This means that I am actually 
measuring differences in gray matter density, which implies atrophy, but is not 
synonymous.  Longitudinal analyses are needed to assess atrophy and 
metabolic changes over time. Additionally, while the rigorous exclusion criteria 
employed in ADNI are typical of clinical trials, this renders the ADNI’s population 
as not representative of the general population. Furthermore, there is very little 
post mortem data currently available for ADNI, which means diagnosis of AD 
largely lacks pathological verification.  Finally, while I am including the 
EOnonADDEM in my report for completeness, one must keep in mind that the 
number of subjects in this group is very small, thus, the findings should be 
interpreted with caution.  Larger research studies such as the recently funded 
Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) which will use 
amyloid imaging and detect EOnonAD cases will be able to define the 
neurodegenerative pattern in this group. 
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2.6. Conclusions: 
In conclusion, my study found a similar neurodegenerative pattern 
between amnestic amyloid-positive EO and LO MCI and DEM subjects. These 
processes were more severe in the EO group indicating a more aggressive 
disease course. I also found that LOnonADDEM subjects show anterior temporal 
neurodegeneration which might reflect the presence HS-TDP-43 or LATE. In the 
absence of reliable in vivo TDP-43 biomarker, the only feasible method of 
confirmation is through post-mortem examination of the brains. Other large 
research consortia such as the recently funded LEADS project will allow the 
opportunity to systematically study EOAD and EOnonAD and further characterize 
these highly understudied disease states.  
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Chapter 3. The effect of the top 20 Alzheimer’s disease risk genes on gray 
matter density and FDG PET brain metabolism 
3.1. Introduction: 
 Alzheimer’s disease (AD) is a chronic neurodegenerative disease 
characterized by short-term memory loss in the early disease stages and 
progressive cognitive and functional deficits as the disease advances. The 
clinical symptoms result from the deposition of two toxic proteins - β-amyloid (Aβ) 
and tau, which give rise to neuritic plaques and neurofibrillary tangles 
respectively 115. The clinical appearance of AD is the direct result of neuronal 
dysfunction and death, which is manifested by brain atrophy and 
hypometabolism.  
  Brain imaging is increasingly utilized to measure AD-associated changes 
in vivo.  Amyloid positron emission tomography (PET), a novel Food and Drug 
Administration approved imaging technology, uses selective Aβ tracers to 
visualize brain amyloidosis and can reliably detect the presence of neuritic 
plaques in the symptomatic and presymptomatic stages.  Brain atrophy is best 
evaluated with longitudinal studies of high-field magnetic resonance imaging 
(MRI). The atrophic changes are first noticeable in the medial temporal lobe, 
eventually spreading through the remainder of the brain as the disease 
progresses 116.  Brain hypometabolism, a decrease in brain metabolic activity, 
can be visualized using [18F]Fluorodeoxyglucose (FDG) PET or single-photon 
emission tomography (SPECT) with 99mTc exametazime. The hallmark pattern in 
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AD is early hypometabolism of the posterior cingulate, lateral temporal and 
parietal lobes with spread to the frontal lobes as the disease progresses 117.  
 Seventy-80% of sporadic Alzheimer’s disease can be attributed to genetic 
risk 118,119. Recent large-scale genome-wide association studies (GWAS) have 
discovered more than 20 AD gene variants that confer genetic risk 75-80. Among 
these variants is the apolipoprotein E (APOE) gene, which is the most 
established genetic risk factor for AD. Individuals with a single APOE4 allele 
have a three-fold increase in AD risk while homozygotes have a 15-fold increase 
120.  APOE is a major protein component of chylomicrons and is highly expressed 
in both liver and brain, where it plays a role in lipid metabolism and is thought to 
be involved in the breakdown of Aβ, both inside and outside of cells.  The APOE4 
protein is less effective in clearing Aβ than the e3 allele, providing a possible 
explanation for the increased risk of amyloid buildup 121.  With the help of imaging 
studies, APOE4 was found to be strongly associated with brain amyloidosis 
122,123, atrophy 124 and hypometabolism 125,126.  These data indicate that valuable 
observations related to gene function can be made with imaging phenotypes. 
 Many of the remaining top 20 AD variants have also been implicated in 
brain metabolism and neurodegeneration.  Several SORL1 variants, EPHA1 
rs11771145 and CR1 rs6656401 were found to be associated with hippocampal 
atrophy and cerebro- or cardio-vascular disease 127,128. Additionally, various 
research groups have shown that ABCA7 rs3764650, MS4A6A rs983392, 
MS4A6A rs610932 and rs11230161, BIN1 rs6733839 and rs744373, CR1 
rs1408077, CR1 rs6656401, CR1 rs3818361, PICALM rs3851179, CLU 
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rs11136000 and rs2279590, CD2AP rs10948363, and CD33 rs3865444 are all 
associated with MRI-measured brain atrophy 129-135. BIN1 rs7561528 was found 
to be significantly associated with both hippocampal volume and FDG PET brain 
metabolism 136.  The studies mentioned have unquestionably contributed to the 
field of imaging genetics and AD research as a whole, but many of these papers 
have either analyzed the effect of a single gene variant at a time 127-130,132,134,135 
or investigated the association between a polygenic risk score with the imaging 
trait, which does not allow for the interpretation of the individual contribution of 
genetic variants 131. The commonly used univariate imaging genetics approach 
ignores the fact that in any given human subject, many of these risk variants are 
simultaneously present, and the genetic contribution of each variant should be 
investigated in the presence of the rest and not in isolation. Additionally, these 
studies have investigated the effects in the pooled samples consisting of 
asymptomatic individuals, of whom only a portion harbor AD pathology, as well 
as symptomatic individuals who are in different stages of the disease.  Such an 
approach would miss any stage-specific associations that might occur for genes 
that influence the timing and course of development of disease traits (e.g., early 
vs. late neurodegeneration or amyloidosis, early vs. late impairment in a specific 
cognitive domain), and/or could explain, at least in part, AD heterogeneity.   
Using a multivariable approach across the disease spectrum allows for 
accurate modeling of this complex polygenic disease that is constantly evolving. 
Here, I report a comprehensive analysis of the associations of well-validated AD 
risk variants from recent large-scale GWAS studies with two markers of 
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neurodegeneration – brain gray matter density (GMD) and brain glucose 
metabolism. My goal was to establish the relative contribution of the top 20 AD 
risk genes to changes in GMD and metabolic dysfunction. I hypothesized that I 
would find gene variants that show a profound effect on these two 
neurodegenerative phenotypes and that some variants will show associations in 
a stage-specific manner. 
This work was performed in conjunction with the published findings of 
Apostolova et el in 2018, which used imaging genetics to explore the association 
of the top 20 Alzheimer’s risk variants to cortical amyloid PET retention 113.  The 
study design, as in the chapters below, uses a multivariable regression model to 
select variants in a polygenic fashion as to establish relative contribution of 
selected genes to amyloidosis.  This study also emphasized the importance of 
modeling throughout each of the disease stages, preclinical to dementia, to 
potentially capture stage-dependent associations.  The results of the regression 
models were then reproduced in a voxelwise fashion as exploratory analysis of 
regional associations.  
 Data included were from 322 cognitively normal, 496 MCI and 159 
dementia subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
who were genotyped and received [18F]Flortbetapir PET scans.   
 The main findings of this work were that outside of the APOE e4 allele, 
ABCA7 rs3752246 had the largest association to amyloidosis.  ABCA7’s 
association with the early stages of the disease (preclinical and MCI) aligns with 
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neurodegeneration dementia findings presented below in chapter 3 and fits along 
the hypothetical dynamic biomarker model proposed by Jack et al in 2010 114.   
Additionally, I found evidence of a stage dependent gene effects in AD. 
The association for FERMT2 rs17125944 was strongest in the MCI stage. This 
observation indicates that a subset of AD genes might exhibit dynamic 
associations across the cognitive continuum. 
 
3.2. Methods: 
Subjects 
 I sourced the study data from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) database (http://adni.loni.usc.edu). ADNI is an international 
longitudinal study with approximately 50 sites across the United States and 
Canada that was launched in 2003. ADNI’s goal is to track the progression of AD 
using clinical and cognitive tests, MRI, FDG PET, amyloid PET, cerebrospinal 
fluid and blood biomarkers (http://adni.loni.usc.edu/study-design).  
ADNI has undergone three study cycles: ADNI1, ADNI GO and ADNI2. 
The study population was composed of participants from all three phases 137. 
The MRI and FDG PET analyses included all subjects with GWAS and baseline 
MRI or FDG PET data that were successfully preprocessed. A total of 1564 ADNI 
subjects had baseline MRI and GWAS data. Of those, 65 failed in the MRI 
preprocessing steps and were excluded from the structural analyses. The final 
MRI cohort consisted of 441 cognitively normal (NC) subjects, 764 mild cognitive 
impairment (MCI) subjects and 294 dementia subjects (total N=1499). As not all 
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ADNI1 subjects received FDG PET, the FDG PET cohort was smaller and 
consisted of 381 NC, 634 MCI and 243 dementia subjects (total N=1258). There 
were 59 subjects with available FDG PET data whose MRI scans failed in the 
preprocessing steps as described above. These subjects were included in the 
FDG PET analyses.  
The clinical characteristics of the ADNI cohort were described previously 
85. Diagnosis of AD was based on the National Institute of Neurological and 
Communicative Disorders and Stroke and the AD and Related Disorders 
Association (NINCDS-ADRDA) criteria 33. AD subjects were required to have 
Mini-Mental State Examination (MMSE) 86 scores between 20 and 26 and a 
Clinical Dementia Rating scale (CDR) score of 0.5–1 at baseline 87. Qualifying 
MCI subjects had memory complaints but no significant functional impairment, 
scored between 24 and 30 on the MMSE, had a global CDR score of 0.5, a CDR 
memory score of 0.5 or greater, and objective memory impairment on Wechsler 
Memory Scale – Logical Memory II test 138. NC subjects had MMSE scores 
between 24 and 30, a global CDR of 0 and did not meet criteria for MCI and AD. 
Subjects were excluded if they refused or were unable to undergo MRI, had other 
neurological disorders, active depression, or history of psychiatric diagnosis, 
alcohol, or substance dependence within the past 2 years, less than 6 years of 
education, or were not fluent in English or Spanish. The full list of 
inclusion/exclusion criteria may be accessed on pages 23–29 of the online ADNI 
protocol (http://www.adni-info.org/Scientists/ADNIStudyProcedures.html). Written 
informed consent was obtained from all participants.  
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Gene Variant Selection and Imputation 
ADNI-1 participants were genotyped using the Illumina Human610-Quad 
BeadChip array, while ADNI-2/GO participants were genotyped using the 
Illumina HumanOmniExpress BeadChip (Illumina, Inc., San Diego, CA). The 
decision to include gene variants was based on the AD GWAS studies that 
discovered these variants to date. Genes previously associated with the defining 
AD pathologic hallmark - amyloid pathology, were also included in the study  
(Table 8) 139-141. The total number of variants selected was 36.  
ABCA7 rs3752246, BIN1 rs6733839, CASS4 rs7274581, CD2AP 
rs9349407, CELF1 rs10838725, INPP5D rs35349669, PTK2B rs2883497, 
SORL1 rs11218343 and SORL1 rs1131497 were not genotyped on either ADNI 
GWAS array or needed full imputation. The following variants were only 
genotyped on one of the platforms and needed partial imputation: NME8 
rs2718058 in ADNI1 and CLU rs933194, DSG2 rs8093731, MEF2C rs190982 
and ZCWPW1 rs1476679 in ADNI-GO/2 (Table 9). The imputation procedures 
have been previously described 142. Imputation was performed using MACH and 
minimac methodology and the 1000 Genomes project (www.1000genomes.org) 
as the reference panel. The accuracy threshold was set at r2=0.30.  
I assessed Hardy-Weinberg equilibrium (HWE) using the --hardy option in 
PLINK.  In the test, I used a quantitative phenotype (global cortical metabolism) 
and a case-control phenotype. The result indicates that all 27 single nucleotide 
polymorphisms (SNPs) do not show any evidence of deviation from HWE (p-
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value > 0.01). The accepted significance threshold for declaring SNPs to be in 
HWE is p-value < 0.001.  
Nine of the 20 genes were represented by more than one SNP. Given that 
such variants could be in linkage disequilibrium (LD) and introduce co-linearity 
bias, I performed LD analyses followed by Cohen’s kappa (κ) statistics (Table 10 
and Figure 7). When variants providing identical information (those with high LD 
and high κ) were detected I chose the SNP with the smallest amount of missing 
data. This reduced the variants from 36 to 27.  
I assessed the allele frequencies for each gene variant. SNPs were coded 
by minor allele dosage except for the following: ABCA7 rs3764650 GG/GT vs. 
TT, CASS4 rs7274581 CC/TC vs. TT, CLU rs9331949 AG/GG vs. AA, DSG2 
rs8093731 TT/TC vs. CC, FERMT2 rs17125944 CC/TC vs. TT and SORL1 
rs112183431 CC/TC vs. TT where the minor allele homozygote frequency was 
less than 2%.  
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Table 8. All variants of the top 20 AD risk genes that were considered for 
inclusion in analyses 
Variants selected were identified in AD GWAS.  Included is minor allele, 
minor allele frequency, odds ratio and the paper(s) where the association was 
found. 
SNPs PAPER MINOR MAF OR CITATIONS 
ABCA7 rs3752246 G 0.17 1.15 [1.09-1.21] Hughes et al., 2014 
ABCA7 rs3764650 G 0.2 1.23 [1.18-1.30] Hollingworth et al., 2011; Shulman et al., 2013 
ABCA7 rs4147929 A 0.18 1.15 [1.11-1.19] Lambert et al., 2013 
BIN1 rs6733839 T 0.39 1.22 [1.18-1.25] Lambert et al., 2009 
BIN1 rs744373 G 0.36 1.17 [1.12-1.21] Seshadri et al., 2010; Hohman et al., 2013; Gharesouran et al., 2014 
BIN1 rs7561528 A 0.2 1.17 [1.13–1.22] Biffi et al., 2010; Naj et al., 2011; Hohman et al., 2013 
CASS4 rs7274581 C 0.09 0.88 [0.84-0.92] Lambert et al., 2013 
CD2AP rs9349407 C 0.19 1.12 [1.07–1.17] Hollingworth et al., 2011; Naj et al., 2011; Shulman et al., 2013 
CD2AP rs10948363 G 0.19 1.1 [1.07-1.13] Lambert et al., 2013 
CD33 rs3865444 A 0.21 0.94 [0.91-0.96] Hollingworth et al., 2011; Naj et al., 2011; Lambert et al., 2013 
CELF1 rs10838725 C 0.26 1.08 [1.05-1.11] Lambert et al., 2013 
CLU rs11136000 T 0.38 0.84 [0.79-0.89] Harold et al., 2009; Lambert et al., 2009; Seshadri et al., 2010 
CLU rs9331949 C 0.1 1.29 [1.09–1.52] Yu et al., 2013 
CLU rs1532278 T 0.26 0.89 [0.85-0.93] Naj et al., 2011 
CLU rs9331896 C 0.38 0.86 [0.84-0.89] Lambert et al., 2013 
CR1 rs12034383 A 0.41 1.32 [1.10–1.59] Brouwers et al., 2012 
CR1 rs3818361 A 0.25 1.18 [1.13-1.24] Thambisetty et al., 2013 
CR1 rs6656401 A 0.07 1.18 [1.14-1.22] Lambert et al., 2009; Lambert et al., 2013 
CR1 rs6701713 A 0.25 1.16 [1.11-1.22] Naj et al., 2011; Shulman et al., 2013 
DSG2 rs8093731 T 0.12 0.73 [0.62–0.86] Lambert et al., 2013 
EPHA1 rs11767557 C 0.2 0.87 [0.83–0.91] Hollingworth et al., 2011; Naj et al., 2011; Hughes et al., 2014 
EPHA1 rs11771145 A 0.43 0.9 [0.88-0.93] Lambert et al., 2013 
FERMT2 rs17125944 C 0.11 1.14 [1.09-1.19] Lambert et al., 2013 
INPP5D rs35349669 T 0.21 1.08 [1.05-1.11] Lambert et al., 2013 
MEF2C rs190982 G 0.22 0.93 [0.90-0.95] Lambert et al., 2013 
MS4A6A rs610932 A 0.45 0.9 [0.87-0.92] Hollingworth et al., 2011 
MS4A6A rs983392 G 0.23 0.9 [0.87-0.92] Lambert et al., 2013 
NME8 rs2718058 G 0.34 0.93 [0.90-0.95] Lambert et al., 2013 
PICALM rs3851179 T 0.31 0.9 [0.83–0.99] Harold et al., 2009; Biffi et al., 2010; Seshadri et al., 2010 
PICALM rs10792832 A 0.31 0.87 [0.85–0.89] Lambert et al., 2013 
PICALM rs561655 G 0.34 0.87 [0.84–0.91] Naj et al., 2011 
PTK2B rs28834970 C 0.32 1.1 [1.08-1.13] Lambert et al., 2013 
SLC24A4/RIN3 
rs10498633 T 0.15 0.91 [0.88-0.94] Lambert et al., 2013 
SORL1 rs11218343 C 0.11 0.77 [0.72-0.82] Lambert et al., 2013 
SORL1 rs1131497 G 0.37 1.92 [1.28–2.90] Seshadri et al., 2007; Zhang et al., 2015 
ZCWPW1 rs1476679 C 0.21 0.91 [0.89-0.94] Lambert et al., 2013 
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Table 9. List of variants that needed partial or full imputation 
 Some variants required imputation using data from the 1000 Genomes 
project.  Need for imputation was dependent on the phase which subjects were 
genotyped. 
 
 
 
 
 
 
 
 
 
 
  
SNP Imputed in 
ABCA7 rs3752246 ADNI-1, ADNI-2/GO 
BIN1 rs6733839 ADNI-1, ADNI-2/GO 
CASS4 rs7274581 ADNI-1, ADNI-2/GO 
CD2AP rs9349407 ADNI-1, ADNI-2/GO 
CELF1 rs10838725 ADNI-1, ADNI-2/GO 
CLU rs9331949 ADNI-1 
DSG2 rs8093731 ADNI-1 
INPP5D rs35349669 ADNI-1, ADNI-2/GO 
MEF2C rs190982 ADNI-1 
NME8 rs2718058 ADNI-2/GO 
PTK2B rs28834970 ADNI-1, ADNI-2/GO 
SORL1 rs11218343 ADNI-1, ADNI-2/GO 
SORL1 rs1131497 ADNI-1, ADNI-2/GO 
ZCWPW1 rs1476679 ADNI-1 
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Table 10. Linkage analysis for genes with multiple variants included 
Linkage disequilibrium and kappa statistics results for the variants retained 
in the analyses. 
  
 
 
 
 
 
 
  
GENE SNP 1 SNP 2 LD (D’) KAPPA 
ABCA7 rs3752246 rs3764650 65 0.38 
BIN1 
rs6733839 rs744373 88 0.58 
rs744373 rs7561528 77 0.7 
rs7561528 rs6733839 63 0.45 
CLU rs11136000 rs9331949 100 -0.01 
CR1 rs12034383 rs3818361 97 0.03 
EPHA1 rs11767557 rs11771145 69 0.32 
SORL1 rs11218343 rs1131497 100 -0.02 
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Figure 7. LD analysis 
 Results from the linkage analysis.  For variants with significant overlap, 
the variant with the least missing data was retained for maximum N.  Figure 7 
shows variants who reside within a linkage block outline in black.  
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MRI and FDG PET data acquisition and analyses 
 The MRI acquisition and preprocessing protocols can be found on 
www.adni-info.org. ADNI MRI data acquisition and preprocessing have been 
previously described elsewhere 143-145.  Briefly, I downloaded pre-processed MRI 
data from LONI IDA (https://ida.loni.usc.edu)146. 785 subjects had 3T scans 
available and for the remaining 715 subjects, I used 1.5T data. MRI field strength 
was included as a covariate in all MRI analyses. I analyzed all scans using voxel-
based morphometry (VBM) in Statistical Parametric Mapping (SPM8), as 
described previously 91,147. Scans were downloaded from the ADNI site in NifTI 
format, co-registered to MNI space, bias corrected, and segmented into gray 
matter (GM), white matter (WM), and cerebrospinal fluid (CSF) compartments 
using SPM templates. GM density maps were converted to 1mm × 1mm × 1mm 
voxel resolution and smoothed using 10 mm full-width half maximum (FWHM) 
Gaussian kernel. Total intracranial volume (ICV) and baseline mean medial 
temporal lobe thickness measures were extracted for each subject using 
Freesurfer version 5.1, as described previously 148,149. The medial temporal 
region of interest included the entorhinal, fusiform, parahippocampal and 
temporopolar cortical areas.  
The FDG PET acquisition and preprocessing protocols can be found on 
www.adni-info.org.  PET scanners and related equipment across sites were held 
to the same qualifications, calibration, and normalization standards, as described 
in detail 92. I downloaded preprocessed FDG PET data from LONI IDA 
(https://ida.loni.usc.edu). These scans were already averaged, aligned to a 
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standard space, re-sampled to a standard image and voxel size (2mm × 2mm × 
2mm), smoothed to a uniform resolution as previously described 92. The 
downloaded images were aligned to each corresponding MRI image on a 
subject-by-subject basis in MNI space using SPM8, as previously described 149. 
Each scan’s intensity was scaled to the pons to create standard uptake value 
ratio (SUVR) images. Finally, baseline mean FDG SUVR in bilateral posterior 
cingulate was extracted for each subject 150,151. 
Statistical Analyses 
R Statistical Analyses: 
The distributions of clinical and demographic characteristics [age, sex, 
education, MMSE, APOE4 genotype, diagnosis] for each variant were analyzed 
using t-tests or Chi-square tests with two-sided p-values as appropriate. 
My main analyses were done in R v3.3.0 (https://www.r-project.org/). First, I 
performed stepwise linear regression with all 27 AD risk variants as predictors 
and age, gender, education and APOE4 genotype as covariates in the pooled 
sample and then in each diagnostic group. I used medial temporal lobe thickness 
or posterior cingulate SUVR, AD biomarkers of neurodegeneration, as outcome 
measures. Additional covariates were the diagnosis in the pooled analyses and 
magnetic field strength and ICV in all MRI analyses. The decision to exclude 
variables in the stepwise regression models was based on the Akaike 
Information Criterion (AIC) using the critical p-value of 0.157 152. Given that all 
the risk genes were previously validated (i.e., all were candidate genes) and I 
used a multivariable model, I set the significance threshold at p<0.05. After 
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discovering stage-specific genetic influences I repeated the pooled sample 
analyses introducing interaction terms between the genetic variants retained in 
the models and diagnosis.  
Analyses in Imaging Space: 
All imaging analyses were done in an exploratory fashion. I reproduced the 
final stepwise regression models using voxel-wise regression in SPM8 for 
visualization purposes in order to explore, on a whole-brain level, the extent and 
spatial pattern of these imaging genetic associations established using a region 
of interest approach. These models included all variants retained in the R 
stepwise linear regression models and were covaried for age, gender and 
APOE4 genotype. Consistent with the original regression model, the pooled 
analyses also included diagnosis as a covariate and the MRI analyses were 
additionally controlled for MRI field strength and ICV. Due to the exploratory 
nature of the secondary results, I used a less stringent visualization voxel-wise 
threshold, which was uncorrected p < 0.01 with a minimum cluster size (k) of 50 
voxels. Next, I report all family-wise error (FWE) and false discovery rate (FDR) 
significant within-cluster peak effects for all genetic variants identified in the 
models.    
 
3.3. Results: 
 Group comparisons of demographic characteristics and distributions of the 
genotypes that were retained in the regression models are shown in Tables 11 
and 12 for the MRI and PET samples, respectively. As expected, AD subjects 
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were the oldest, least educated, had the greatest frequency of APOE4 and 
performed the worst on MMSE (Tables 11 and 12). There were no significant 
differences in age, gender, education, MMSE and APOE4 distribution between 
carriers and non-carriers or by allele dosage for any of the genotypes except the 
following: DSG2 minor allele carriers were more likely to be male (p=0.028 in the 
FDG sample) and less likely to be APOE4 carriers (p=0.04 in the MRI sample); 
EPHA1 rs11767557 minor allele carriers were less likely to be APOE4 carriers 
and had significantly higher MMSE scores in the FDG sample (p=0.037 and 
p=0.047, respectively); SORL1 rs11218343 minor allele carriers were less 
educated and more likely to be male in both samples (MRI: p=0.01 and p=0.008, 
and FDG p=0.008 and p=0.026, respectively), and  ZCWPW1 risk allele carriers 
were significantly less educated and had higher MMSE scores in both samples 
(MRI p=0.0012 and p=0.034, and FDG p=0.025  and p=0.034, respectively).  For 
completeness, the allele dosage for all 27 variants including the ones not 
retained in the models can be seen in Tables 13 and 14.  
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Table 11. MRI descriptives  
Descriptive characteristics and distribution of the genotypes of the study 
groups who received MRI. 
VARIABLES NC (N=441) 
MCI 
(N=764) 
DEM 
(N=294) p-value 
Age, mean years (SD) 74.1 (5.7) 72.6 (7.6) 74.6 (7.9) <0.001 
Sex, N male (%) 222 (50%) 453 (59%) 165 (56%) 0.010 
Education, mean years (SD) 16.4 (2.6) 16.0 (2.8) 15.2 (3.0) <0.001 
MMSE, Mean (SD) 29.1 (1.1) 27.6 (1.8) 23.3 (2.1) <0.001 
APOE4, %0/1/2 71/27/2 49/40/11 34/47/19 <0.001 
ABCA7 rs3752246, % 0/1/2 69/29/2 68/28/4 67/30/3 0.580 
CELF1 rs10838725, % 0/1/2 46/45/9 44/46/10 45/48/7 0.450 
EPHA1 rs11771145, % 0/1/2 44/44/12 43/45/12 45/42/13 0.950 
FERMT2 rs17125944, % 0/1 85/15 84/16 78/22 0.020 
INPP5D rs35349669, % 0/1/2 30/48/22 30/46/24 26/51/23 0.520 
SLC24A4/RIN3 rs10498633, % 
0/1/2 60/35/5 61/34/5 60/35/5 0.990 
ZCWPW1 rs1476679, % 0/1/2 50/41/9 51/41/8 60/33/7 0.080 
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Table 12. FDG descriptives  
Descriptive characteristics and distribution of the genotypes of the study 
groups who received FDG PET 
VARIABLES NC (N=381) 
MCI 
(N=634) DEM (N=243) p-value 
Age, mean years (SD) 74.3 (6.2) 72.6 (7.6) 75.0 (7.7) <0.001 
Sex, N male (%) 190 (50%) 380 (60%) 148 (61%) 0.003 
Education, mean years (SD) 16.4 (2.7) 16.1 (2.7) 15.4 (2.9) <0.001 
MMSE, Mean (SD) 29.0 (1.2) 27.8 (1.8) 23.1 (2.8) <0.001 
APOE4, %0/1/2 73/25/2 51/38/11 33/50/17 <0.001 
CD2AP rs9349407, % 0/1/2 49/44/7 53/40/7 49/40/11 0.220 
CELF1 rs10838725, % 0/1/2 48/42/10 44/46/10 43/50/4 0.270 
CLU rs11136000, % 0/1/2 36/50/14 37/50/13 43/42/15 0.280 
CLU rs9331949, % 0/1 95/5 97/3 95/5 0.310 
CR1 rs12034383, % 0/1/2 14/49/37 15/48/37 21/46/33 0.190 
DSG2 rs8093731, % 0/1 98/2 98/2 97/3 0.840 
EPHA1 rs11771145, % 0/1/2 44/44/12 45/42/13 43/44/13 0.940 
EPHA1 rs11767557, % 0/1/2 66/30/4 70/27/3 63/34/3 0.290 
MS4A6A rs610932, % 0/1/2 31/48/21 37/47/16 38/45/17 0.250 
NME8 rs2718058, % 0/1/2 39/47/14 40/45/15 38/49/13 0.880 
PTK2B rs28834970, % 0/1/2 42/42/16 42/42/16 39/49/12 0.390 
SLC24A4/RIN3 rs10498633, % 0/1/2 61/34/5 62/34/4 58/37/5 0.870 
SORL1 rs11218343, % 0/1 91/9 92/8 93/7 0.550 
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Table 13. MRI FWE and/or FDR significant clusters 
Family-wise error (FWE) and False Discovery Rate (FDR) corrected 
cluster analyses and within-cluster peak effects for the genetic variants identified 
in the exploratory MRI analyses   
 
NC – Cognitively normal; DEM - Dementia; pFWE-corr - Family Wise 
Error-corrected p-value; qFDR-corr - False Discovery Rate-corrected q-value; kE 
- cluster size; puncorr: - uncorrected p-value; T -T statistic 
  
DX 
Group 
Gene variant 
cluster-level peak level 
Talairach 
coordinates 
Brain 
Region 
(Brodmann 
Area, BA)  
DEM 
pFWE-
corr 
qFDR-
corr kE puncorr T puncorr 
ABCA7 
rs3752246 <0.0001 <0.0001 924757 <0.0001 9.72 <0.0001 -11 -23 63 
L medial 
frontal 
gyrus (BA6) 
EPHA1 
rs11771145 
0.04 0.051 13081 0.001 3.86 <0.0001 -52 -28 61 
L 
postcentral 
gyrus (BA2) 
0.007 0.017 1889 <0.0001 4.01 <0.0001 52 -30 59 
R 
postcentral 
gyrus (BA2) 
SLC24A4/RIN3 
rs10498633 0.007 0.012 18621 <0.0001 3.78 <0.0001 -14 1 46 
L cingulate 
gyrus 
(BA24) 
  65 
Table 14. FDG FWE and/or FDR significant clusters 
Family-wise error (FWE) and False Discovery Rate (FDR) corrected 
cluster-level analyses and within-cluster peak effects for genetic variants 
identified in the exploratory FDG PET analyses   
Dx 
Group 
Gene variant 
Cluster Peak Effect 
Talairach 
coordinates 
Brain Region 
(Brodmann 
Area, BA) 
POOLED 
SAMPLE 
pFWE-
corr 
qFDR-
corr kE puncorr T puncorr 
CLU 
rs1113600 
<0.0001 <0.0001 5979 <0.0001 4.02 <0.0001 -48 -4 -32 
L inferior 
temporal gyrus 
(BA20) 
0.027 0.025 1493 <0.0001 4.01 <0.0001 64 -18 8 
R transverse 
temporal gyrus 
(BA42) 
EPHA1 
rs11771145 0.049 0.102 1314 0.0001 3.8 <0.0001 -14 -50 60 
L superior 
parietal lobule 
(BA7) 
MS4A6A 
rs610932 0.001 0.001 2723 <0.0001 4.28 <0.0001 40 -14 42 
R precentral 
gyrus (BA4) 
PTK2B 
rs28834970 0.002 0.003 2426 <0.0001 3.96 <0.0001 -2 -74 -2 
L lingual gyrus 
(BA18) 
NC 
CELF1 
rs10838725 
0.004 0.004 1960 <0.0001 4.19 <0.0001 20 -66 44 R precuneus (BA7) 
<0.0001 <0.0001 2718 <0.0001 3.88 <0.0001 0 52 -12 L medial frontal gyrus (BA10) 
0.017 0.012 1514 <0.0001 3.5 <0.0001 32 -38 -4 R sub-gyral, hippocampus 
CR1 
rs12034383 <0.0001 <0.0001 37014 <0.0001 4.98 <0.0001 18 -36 30 
R cingulate 
gyrus (BA31) 
DSG2 
rs8093731 0.017 0.008 1515 <0.0001 4.15 <0.0001 6 -4 50 
R medial frontal 
gyrus (BA6) 
PTK2B 
rs28834970 
<0.0001 <0.0001 6279 <0.0001 4.24 <0.0001 44 -22 6 
L superior 
temproral gyrus 
(BA13) 
<0.0001 <0.0001 6722 <0.0001 3.98 <0.0001 -42 -36 12 
L superior 
temproral gyrus 
(BA41) 
SLC24A4/RIN3 
rs10498633 
<0.0001 <0.0001 20054 <0.0001 4.38 <0.0001 22 -4 -30 
R 
parahippocampal 
gyrus (BA36) 
0.007 0.004 1767 <0.001 3.71 <0.0001 -22 -8 -30 
L 
parahippocampal 
gyrus(BA36) 
DEM NME8 rs2718058 <0.001 <0.001 3551 <0.001 4.52 <0.0001 -14 -88 30 L cuneus (BA19) 
 
NC – Cognitively normal; DEM - Dementia; pFWE-corr - Family Wise 
Error-corrected p-value; qFDR-corr - False Discovery Rate-corrected q-value; 
kE - cluster size; puncorr: - uncorrected p-value; T -T statistic  
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APOE4 showed the expected negative association with GMD in the NC 
and MCI group (Figure 8 top). In the symptomatic MCI group, I saw a strong 
hippocampo-centric pattern, indicating that MCI carriers had greater hippocampal 
loss of GMD compared to MCI noncarriers. In the dementia group, I found the 
opposite association. APOE4-negative dementia subjects had greater cortical 
loss of GMD than APOE4-positive subjects, indicative of greater cortical 
neurodegeneration. APOE4 was associated with widespread hypometabolism in 
the MCI group (Figure 8 bottom). APOE4 showed a much less pronounced 
effect in the dementia stage indicating that both carriers and noncarriers 
experienced significant, widespread hypometabolic changes.  
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Figure 8. APOE4 effect 
APOE4 Effect on brain atrophy (top) and hypometabolism (bottom). 
Results are displayed using p < 0.01 (uncorrected) and cluster size (k) of 50 
voxels. 
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MRI Analyses 
Pooled sample: 
In the pooled sample the stepwise linear regression model achieved an 
R2=0.4, p<0.0001. SLC24A4/RIN3 rs10498633 was the only variant that was 
significantly associated with mean medial temporal lobe thickness in the pooled 
sample (χ2=11.8, p=0.003). ABCA7 rs3752246 and FERMT2 rs17125944 were 
retained in the regression output based on the selection criteria but were not 
statistically significant. See Figure 9 for the exploratory visualization of these 
associations and Table 13 for FWE- and FDR-corrected cluster-level results and 
within-cluster peak effects for genetic variants identified in the models.    
Analyses within diagnostic groups: 
I found neither significant nor trend level associations in the NC group. In the 
MCI group the model achieved an R2=0.26. SLC24A4/RIN3 rs10498633 
(χ2=11.3, p=0.004) and ZCWPW1 rs1476679 (χ2=7.3, p=0.026) reached 
significance. CELF1 rs10838725 (χ2=5.2, p=0.073) was trending. In the dementia 
group the model achieved an R2=0.19, p<0.0001. ABCA7 rs3752246 (χ2=8.5, 
p=0.014), EPHA1 rs11771145 (χ2=11.6, p=0.003) and INPP5D rs35349669 
(χ2=6.4, p=0.042) were significantly associated with mean medial temporal lobe 
thickness. SLC24A4/RIN3 rs10498633 (χ2=5.4, p= 0.068) was trending. See 
Figure 9 for the exploratory pattern of these associations.  
 Next, I repeated the pooled sample analyses introducing interaction terms 
between the genetic variants retained in the models and diagnosis. The following 
variants showed significant interaction effect with diagnosis - EPHA1 rs11771145 
  69 
(F=3.2, p=0.01) and SLC24A4/RIN3 (F=2.7, p=0.03). Please note that the R 
statistical analyses and the analyses in imaging space might differ as in the R 
statistics model I use a circumscribed ROI – in the case of MRI the medial 
temporal region while the whole brain exploratory results show the effect of the 
variant across the brain.  
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Figure 9. MRI SPM results 
Regression selected genes associated with MRI measured GMD. Results are 
displayed at significance threshold of uncorrected p < 0.01 and minimum cluster 
size (k) of 50 voxels. 
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FDG PET Analyses 
Pooled sample: 
  In the pooled sample, the stepwise linear regression model achieved an 
R2=0.13, p<0.0001. EPHA1 rs11767557 showed significant associations with 
brain metabolism (χ2=6.3, p=0.042). PTK2B rs28834970 (χ2=5.6, p=0.059), 
MS4A6A rs610932 (χ2=5.5, p=0.065) and SLC24A4/RIN3 rs10498533 (χ2=4.6, 
p=0.098) showed trend level associations. CLU rs11136000 and EPHA1 
rs11771145 were included in the model based on the selection criteria but were 
not statistically significant.  
See Figure 10 for the exploratory visualization of these associations and 
Table 14 for FWE- and FDR-corrected cluster-level results and within-cluster 
peak effects for genetic variants identified in the models.    
Analyses within diagnostic groups: 
  In the NC group the stepwise linear regression model achieved an 
R2=0.14, p<0.0001. SLC24A4/RIN3 rs10498533 (χ2=6.3, p=0.043), NME8 
rs2718058 (χ2=6.0, p=0.049) and CD2AP rs9349407 (χ2=6.1, p=0.048) showed 
significant associations, while DSG2 rs8093731 (χ2=3.4, p=0.064), CR1 
rs12034383 (χ2=4.9 p=0.087), and CELF1 rs10838725 (χ2=5.386, p=0.068) were 
trending. CLU rs9331949 and PTK2B rs28834970 were included in the model 
based on the selection criteria but were not statistically significant. In the MCI 
group, the stepwise linear regression model achieved an R2=0.09, p<0.0001.  
CLU rs9331949 was trending (χ2=3.4, p=0.065) while MS4A6A rs610932 was 
included based on the selection criteria but was not statistically significant. In the 
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dementia stage the model achieved an R2=0.07, p=0.034. SORL1 rs11218343 
showed trend level significance (χ2=3.5, p=0.063) while NME8 rs2718058 and 
CD2AP rs9349407 were included based on the selection criteria but were not 
statistically significant. See Figure 10 for the exploratory visualization of these 
associations.  
 Next, I repeated the pooled sample analyses introducing interaction terms 
between the genetic variants retained in the models and diagnosis. The following 
variants showed significant interaction effect with diagnosis - CD2AP rs9349407 
(F=2.4, p=0.04), CLU rs9331949 (F=3.5 p=0.03) and NME8 rs2718058 (F=3.1, 
p=0.01). CR1 rs12034383 (F=2.3, p=0.06) and SORL1 rs11218343 (F=2.9 
p=0.06) showed trend level interactions. Please note that the R statistical 
analyses and the analyses in imaging  space might differ as in the R statistics 
model I use a circumscribed ROI – in the case of FDG PET the posterior 
cingulate region while the whole brain exploratory results show the effect of the 
variant across the brain.    
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Figure 10. FDG SPM results 
Regression selected genes associated with FDG PET measured brain 
metabolism. Results are displayed at significance threshold of uncorrected p < 
0.01 and minimum cluster size (k) of 50 voxels. 
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3.4. Discussion: 
 To my knowledge, this is the first comprehensive analysis of the effect of 
the top 20 AD risk variants on MTL GMD and PCC brain metabolism. In the MRI 
analyses, I found no genetic influences on GMD in NC. In the MCI stage, 
SLC24A4/RIN3 rs10498633 and ZCWPW1 rs1476679 showed significant effects 
while in the dementia stage ABCA7 rs3752246, EPHA1 rs11771145 and INPP5D 
rs35349669 were significantly associated with GMD. In the FDG PET analyses, 
the only significant associations were seen in the NC control group for 
SLC24A4/RIN3 rs10498533, NME8 rs2718058 and CD2AP rs9349407. The 
reported associations of ABCA7, ZCWPW1, and INPP5D with GMD, and CD2AP 
with PCC brain metabolism are novel.   
Many of the variants displayed stage-specific associations, which is likely 
due to the nature of AD pathological biomarker changes from the 
presymptomatic stage to dementia.  These stage-specific associations are in 
agreement with the biomarker progression as proposed by Jack et al.114 . Jack’s 
biomarker progression model postulates that neurodegenerative changes begin 
in the late asymptomatic stages as NC individuals start to transition to MCI 114 
and that FDG PET abnormalities precede brain atrophy 114. Both 
neurodegenerative biomarkers become progressively more abnormal over the 
course of the disease. My findings agree with this model.  The results indicate 
neither significant nor trend level associations with GMD in the NC group, but 
significant associations were detected in the MCI and dementia stages. I also 
see a modality effect progression that fits with the Jack model. SLC24A4/RIN3 
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shows significant association with brain metabolism in the presymptomatic 
stages and associations with GMD in the MCI group.   
 Recent analyses on the top 20 AD genes and brain amyloidosis revealed 
that, after APOE4, ABCA7 had the strongest effect on brain amyloidosis, with the 
effect being most pronounced in the MCI stage 153. In the present study, I 
observe a strong association of ABCA7 with GMD in the dementia group. These 
associations also seem to follow the biomarker progression, as Aβ deposition 
begins in the presymptomatic to early MCI phase and global decreases in GMD 
begins in late MCI to dementia phase. Associations of ABCA7 with brain atrophy 
129 and amyloidosis 139-141 have been previously reported.  
In a similar manner, my previous work showed that EPHA1’s strongest 
effect on brain amyloidosis is in the prodromal phase 153. In the present study, 
the MRI results show a significant association with GMD in the dementia stages 
only.  To date, two additional studies have described EPHA1 associations with 
brain atrophy 154,155 and one  also detected an association with brain metabolism 
as I did here 154.    
 Next, I found it pertinent to briefly review the literature on the function and 
central nervous system associations for each of the genes in the models.  
 
ABCA7 
 ATP-Binding Cassette Sub-Family A Member 7 (ABCA7) encodes a 2,146 
amino acid member of the ABC transporter family comprised of proteins involved 
in lipid transport 156.  ABCA7 is highly expressed in the central nervous system 
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and in microglia 157. Loss of function of endogenous ABCA7 increases β-
secretase cleavage of APP to Aβ in brain lysates and in murine models 158. 15 
ABCA7 loci were recently evaluated for associations with cerebrospinal fluid Aβ 
and tau levels, brain atrophy, and brain hypometabolism.  Several ABCA7 
variants had significant associations with amyloid deposition, though an 
association with brain atrophy was not reported there 159. However, another 
group has previously found such an association in a different independent 
imaging genetic cohort 129. Additionally, one rare missense mutation variant of 
ABCA7, rs7297358, was found to be protective for AD 160.  
 
CD2AP 
 The CD2 associated protein gene (CD2AP) encodes a 639 amino acid 
scaffolding protein that is named by its association with the T-cell and natural 
killer cell adhesion molecule cluster of differentiation 2 (CD2). CD2AP is a 
cytokinetic regulator that might be influencing neuronal survival by reducing the 
potency of glial cell derived neurotrophic factor 161. In cell culture, CD2AP 
suppression results in lower levels of APP, less Aβ release, and a lower 
Aβ42/Aβ40 ratio while having little to no effect on Aβ deposition 162. CD2AP 
knockdown significantly increases Aβ protein levels while APP remained at a 
similar level to the wild-type 163. Recent research in CD2AP knockout mice shows 
that CD2AP’s association with LOAD risk may be at least in part due to an effect 
on the cerebrovascular unit 164. To my knowledge, there are no reported imaging 
associations of CD2AP to date. 
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EPHA1 
EPH Receptor A1 (EPHA1) belongs to the EPH family of receptor tyrosine 
kinases. EPHA1 codes for a 976 amino acid protein with a single kinase domain 
165. EPHA1 is highly expressed in cerebral cortex and hippocampus 
(http://www.proteinatlas.org/ENSG00000146904-EPHA1/tissue) and plays a 
crucial role in cortical and axonal development 166,167. EPHA1 directs contact-
dependent bidirectional signaling by binding the membrane-bound ephrin-A 
family of ligands 168,169. As already discussed, EPHA1 has been previously 
associated with brain atrophy and brain metabolism 154,155. 
 
INPP5D 
 Inositol Polyphosphate-5-Phosphatase D (INPP5D) encodes a 1,888 
amino acid protein that plays a role in a number of inflammatory pathways and in 
regulation, of cytokine signaling 170,171. INPP5E, a closely related gene to 
INPP5D, is a crucial regulator of autophagy 172. Autophagy has been shown in 
many instances to be dysregulated in AD 173-175. INPP5D may also play a role in 
suppression of cytokine release from microglia or astrocytes 176. INPP5D has 
been significantly associated with several central nervous system pathologies, 
including macroscopic and microscopic infarcts, Lewy bodies, and hippocampal 
sclerosis 177.            
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NME8 
NME Family Member 8 (NME8) encodes a 588 amino acid protein kinase. 
Until recently NME8 was associated with non-neurologic diseases such as 
primary ciliary dyskinesia 178 and osteoarthritis 179,180. In a recent ADNI study, 
however, NME8 rs2718058 was shown to have a neuroprotective effect against 
hippocampal atrophy and brain hypometabolism 181.  
 
SLC24A4/RIN3 
 Solute Carrier Family 24 (Sodium/Potassium/Calcium Exchanger) Member 
4 (SLC24A4)/Ras and Rab Interactor 3 (RIN3) are indicated in AD together 
because the candidate polymorphism lies between both genes on chromosome 
14q32.12. SLC24A4 encodes a 622 amino acid potassium-dependent sodium-
calcium exchanger 182. SLC24A4 appears to take part in lipid metabolism 183. 
SLC24A4 CpG methylation sites were also associated with Aβ burden and tau 
pathology 184.   In a recent study, SLC24A4 knockout mice showed brain glucose 
hypometabolism 185. Interestingly, I found a similar effect in NC.  
RIN3 encodes a 985 amino acid guanine exchange factor for RAB5B and 
RAB31 and plays an important role in the transport of early endosomes 186,187. In 
a transgenic model, a mutation in APP was shown to contribute to early 
endosomal abnormalities and enlargement, which leads to loss of cholinergic 
neurons 188. RAB GTPase expression is increased in MCI subjects and in aging 
brains 189. RIN3 also interacts with BIN1, which has recently been linked to tau 
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pathology 190.  To my knowledge there are no reported imaging associations of 
RIN3 to date.  
 
ZCWPW1 
Zinc Finger CW-Type and PWWP Domain Containing 1 (ZCWPW1) codes 
for a 648 amino acid protein that has recently been identified as a risk variant for 
late-onset AD 191. Zinc fingers including ZCWPW1 are crucial components of 
epigenetic regulation 192-194. To my knowledge, there are no reported imaging 
associations of ZCWPW1 to date. 
The APOE4 effect on cortical gray matter density warrants some 
discussion. Structurally, I found the expected negative association of APOE4 with 
gray matter density in NC and MCI with a strong predilection for the medial 
temporal lobe. In the dementia group, however, APOE4-negative individuals 
showed more profound atrophy than APOE4 carriers with a broad neocortical 
distribution. Given that a far greater proportion of APOE4 negative dementia 
subjects were amyloid negative (94% vs. 28% of the amyloid positive dementia 
subjects, p<0.0001) one could safely conclude that the profound cognitive 
decline of many of these subjects is due to other neurodegenerative diseases. 
Thus, the finding greater atrophy in APOE4 noncarrier dementia subjects in 
extra-hippocampal locations is not surprising. 
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3.5. Strengths and Limitations: 
Several strengths and limitations of my work are worth noting. The major 
strength of my study is the multivariable approach.  This allows for more accurate 
modeling of the associations with AD biomarkers as they exist in vivo. Using 
ADNI is another strength as the ADNI protocol includes a rigorous clinical, 
biomarker, and genetic characterization for all enrolled subjects. By standardizing 
their data collection and processing strategies ADNI minimizes between-site 
variations as much as possible. ADNI is a multisite study modeled by clinical 
trials. As such, ADNI uses more stringent inclusion and exclusion criteria typical 
of clinical trial methodology. Hence all observations made here need to be further 
replicated in the general population. Another limitation is that the study design is 
a cross-sectional analysis. From the data alone it is not possible to reliably draw 
conclusions about changes in metabolism or atrophy over time.  I do, however, 
intend to address this in future studies by taking a longitudinal approach to my 
work. Despite this limitation, this study has identified several key genes they may 
exert their effect in specific stages, which need to be examined in future 
research.  
 
3.6. Conclusions: 
In conclusion, I found several AD risks and protective loci that may play a 
key role in GMD and brain metabolism.  I also noted stage-specific associations 
for certain variants, which may follow a specific progression of AD biomarkers 
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throughout the disease.  Importantly, many of these stage associations take 
place in the context of the proposed biomarker timeline.  
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Chapter 4. Association of the top 20 Alzheimer’s disease risk genes with 
[18F]Flortaucipir PET 
4.1. Introduction: 
An estimated 5.8 million people in the United States currently living with 
Alzheimer’s disease (AD) 2.  In contrast to the dominantly inherited mutations 
attributed to familial early-onset AD, which are seen in amyloid precursor protein 
(APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes, sporadic AD 
arises from a variety of risk factors both genetic and environmental 68-70.   
Understanding the complex network of genetic risk factors contributing to 
sporadic AD has been challenging.  For a long time, the only risk gene 
associated with sporadic AD was the apolipoprotein E (APOE) gene. APOE has 
a dose-dependent risk, where one copy of the e4 allele triples AD risk while two 
copies increase risk by as much as 15-fold. Although this variant confers a large 
amount of risk, current estimations cite APOE e4 (APOE4) as accounting for less 
than half of the total genetic hazard 73,195.  
To explain the remaining genetic component, large-scale genome-wide 
association studies (GWAS) and meta-analysis of GWAS have identified risk 
variants near 20 genes involved in pathways such as cholesterol metabolism, 
immune response and endocytosis 78-80,196-198.  Though each of these variants 
contributes to a relatively small amount of the overall risk, inheriting multiple risk 
alleles may result in summation and a greater overall risk profile.  Though 
function is known for many of the genes, a small number have no certain 
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function, and even fewer are understood as they relate to dysfunction seen 
during the progression of Alzheimer’s.  
Through the use of imaging genetics, I previously associated the top AD 
GWAS-identified variants with amyloidosis, brain metabolism and atrophy 113,199. 
In addition to using a polygenic model to find variant associations with AD-
specific disease biomarkers or endophenotypes, I found stage-dependent 
associations with FERMT2 (amyloid positron emission tomography, PET), 
EPHA1 and SLC24A4/RIN3 (MRI) and CD2AP, CLU and NME8 (FDG PET) in 
each of the three diagnostic groups, cognitively normal (CN), mild cognitive 
impairment (MCI) and AD dementia (DEM) subjects, indicating that the genetic 
impact on AD evolves as the disease progresses. This strategy was particularly 
important to better understanding genotype-endophenotype interactions in AD, 
which follows a known pathophysiologic progression consisting of early amyloid 
deposition followed many years later by the accumulation of tau and finally 
neuronal degeneration 26.   
The addition of tau PET neuroimaging to ADNI protocol affords the 
opportunity to conduct a comprehensive polygenic analysis of the associations of 
GWAS-validated AD risk variants with cortical tau burden, which was measured 
via [18F]Flortaucipir PET. The goal of this study was to establish the relative 
genetic contribution to tau burden using stepwise multivariable regression as I 
have done previously for brain amyloidosis and neurodegeneration 113,199.  
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4.2. Methods: 
Participants 
Data used in the preparation of this article were obtained from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu).  
ADNI was launched in 2003 as a public-private partnership, led by Principal 
Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test 
whether serial MRI, PET, other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of 
MCI and early AD. For up-to-date information, see www.adni-info.org. 
 The clinical description of the ADNI cohort has been previously published 
85,200,201.  Diagnosis of AD was based on the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association criteria 33,34,202. Individuals with AD dementia were 
required to have Mini-Mental State Examination (MMSE) 86 scores between 20 
and 26 and a Clinical Dementia Rating (CDR) score of 0.5 to 1 at baseline 87. 
Qualifying individuals with MCI had memory concerns but no significant 
functional impairment, scored between 24 and 30 on the MMSE, had a global 
CDR score of 0.5, had a CDR memory score of 0.5 or greater, and had objective 
memory impairment on the Wechsler Memory Scale–Logical Memory II test 203. 
The controls had MMSE scores between 24 and 30, had a global CDR score of 0 
and did not meet criteria for MCI and AD. Individuals were excluded if they 
refused or were unable to undergo MRI, had other neurologic disorders, active 
depression, a history of psychiatric diagnosis, a history of alcohol or other 
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substance dependence within the past 2 years, had less than 6 years of 
education, or were not fluent in English or Spanish. The full list of inclusion and 
exclusion criteria are listed in the online ADNI protocol 
(http://adni.loni.usc.edu/wp-
content/uploads/2010/09/ADNI_GeneralProceduresManual.pdf). Written 
informed consent was obtained from all participants. Only de-identified data were 
used in these analyses. 
I included all ADNI subjects with available genetic data and 
[18F]Flortaucipir scans. This resulted in a sample containing 135 CN, 98 MCI and 
43 DEM subjects.    
Gene Variant Selection and Imputation 
Participants were genotyped using either the Illumina Human610-Quad 
BeadChip (ADNI 1) or Illumina HumanOmniExpress BeadChip (ADNI GO/2) 
arrays and intensity data was processed using GenomeStudio v2009.1 according 
to Illumina Inc. protocols.  
Similar to my previous studies, I narrowed my focus to variants in the top 
20 well-established AD risk genes identified and validated in the largest AD 
GWAS to date. I also included all other variants contained within these genes 
that have previously been associated with brain amyloidosis. The full list, which 
contained a total of 36 variants, can be seen in Table 8. 
Missing genotypes (Table 9) were imputed using MACH and minimac, 
relying on the 1000 Genomes project data as a reference panel. Posterior 
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probabilities of the imputed genotypes for each individual were determined in 
minimac, where I used a threshold of r2=0.30 to accept the imputed genotype.   
For the nine genes containing more than one SNP, I performed linkage 
disequilibrium analysis (LD), followed by Cohen κ statistics to guard against 
collinearity bias (Table 10 and Figure 7). In situations where variants had 
significant overlap (high LD and high κ), I retained the variant with the least 
amount of missing data. 27 variants were included in the final regression models 
including multiple variants from the ABCA7, BIN1, CLU, CR1, EPHA1 and 
SORL1 genes that were not in LD. 
Genotypes were coded by the copy number of the minor alleles (0/1/2 
copies), however, when minor allele homozygote frequency was less than 2% 
the genotype was collapsed into the presence or absence of minor allele (coded 
as 1 and 0, resp.). This was the case for five of the variants; ABCA7 rs3764650, 
CASS4 rs7274581, CLU rs9331949, DSG2 rs8093731, FERMT2 rs17125944, 
and SORL1 rs11218343. 
[18F]Flortaucipir PET Data Acquisition Protocol and Analyses 
Standardized [18F]Flortaucipir acquisition and preprocessing protocols can 
be found at www.adni-info.org. In the main analysis, I downloaded the ADNI UC 
Berkeley [18F]Flortaucipir partial volume corrected (PVC) standardized uptake 
value ratio (SUVR) Freesurfer 6.0 defined regions from ADNI’s website 
(http://adni.loni.usc.edu), where the processing methods for UC Berkeley can 
also be found. I computed a size-weighted Alzheimer’s-specific meta-ROI using 
the a priori regions defined by Jack et al. in 2016, which contains entorhinal, 
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amygdala, parahippocampal, fusiform, inferior temporal, and middle temporal 
regions 204,205. The meta-ROI was then intensity-normalized to the inferior 
cerebellar grey-matter reference region (defined by UC Berkeley using the SUIT 
template) 206.  Meta-ROI SUVRs were then matched to subject genotype data. 
Statistical Analysis 
Clinical, demographic, and biomarker values of interest (age, sex, 
educational level, APOE e4 genotype, MMSE, [18F]Florbetapir mean cortical 
SUVR and [18F]Flortaucipir meta-ROI SUVR) for each diagnostic group (CN, MCI 
and DEM) were compared using ANOVA or χ2 tests with 2-sided p-values as 
appropriate. Variant association with [18F]Flortaucipir meta-ROI SUVR was 
determined using multivariable stepwise linear regression models in SAS 9.4, 
with all 27 AD risk variants, first in the pooled sample and then in each diagnostic 
category using [18F]Flortaucipir meta-ROI SUVR as the outcome measure. All 
regression models included age, sex, and APOE e4 genotype as covariates, 
while the pooled sample also controlled for diagnosis. Model selection was based 
on the Akaike information criterion (AIC) critical p-value threshold of 0.157 152. I 
also provide false discovery rate (FDR)-corrected p-values for each variant 
retained to protect against type I errors. 
Analysis in Imaging Space 
  Next, I visualized the selected variant spatial effects in SPM12. 
Preprocessed [18F]Flortaucipir scans were downloaded from ADNI, where PET 
frames were coregistered, averaged, image and voxel size were standardized 
and smoothed to a uniform resolution. Using SPM12, each subject’s pre-
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processed [18F]Flortaucipir scan was then coregistered to that subject’s closest-
visit MRI, normalized into MNI space and intensity normalized to the cerebellar 
crus to generate SUVR images. To visualize the spatial distribution of the genetic 
associations, I reproduced the regression models using voxelwise regression in 
SPM12, limited to those which survived AIC thresholding. As with the regression 
modeling in SAS, I covaried for age, sex, and APOE e4 genotype, including 
diagnosis as a covariate in the pooled sample. Due to the exploratory nature of 
these secondary results, I employed a less stringent voxelwise threshold of 
uncorrected p < 0.01 with a minimum cluster size (k) of 50 voxels. Following this I 
displayed familywise error (FWE)- and false discover rate (FDR)-corrected 
cluster-level and within-cluster peak effects for each variant.   
 
4.3. Results: 
 Group comparisons of demographic, biomarker and carrier distribution of 
variants retained in the regression models are seen in Tables 15 and 16. The 
sample included 135 CN, 98 MCI and 43 DEM subjects who had available 
GWAS and [18F]Flortaucipir data.  There were no significant differences in age 
between groups (p=0.078). There were, however, significantly more male 
participants in the MCI than in the other groups (p=0.041). DEM subjects had 
significantly less education and more APOE4 carriers than the other two groups 
(p=0.015 and p=0.003). I also observed the expected differences in MMSE, 
[18F]Flortaucipir SUVR and [18F]Florbetapir SUVR across diagnostic groups 
(p<0.001 for all). There were no significant diagnostic group differences in minor 
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allele distribution for any of the gene variants selected in the regression models 
except for SLC24A4/RIN3 rs10498633, which had significantly more 
homozygous carriers in the MCI group (p=0.030). APOE4 showed significant 
association with tau in the pooled, CN and MCI sample while only minimally so in 
the DEM group (Figure 11). 
 Investigating for demographic differences between risk gene dosages, I 
observed no significant differences in age, sex, education or APOE4 carrier 
percentage by minor allele distribution among the variants retained in the 
regression. All the models were corrected for age, gender and APOE4. 
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Table 15. Demographic and biomarker data for each diagnostic group 
This table shows a demographic, neuropsychological and imaging 
measure comparison across each of the diagnostic groups, using ANOVA and 
chi-square p-values where necessary.   
 
  
Variables CN (N=135) 
MCI 
(N=98) 
DEM 
(N=43) p-value 
Age, mean years (SD) 77.7 (6.7) 79.1 (7.1) 80.3 (8.1) 0.078 
Sex, % male 50.4 66.3 51.2 0.041 
Education, mean years 
(SD) 16.9 (2.4) 16.2 (3.1) 15.6 (2.6) 0.015 
APOE4 carrier, % Yes 30.4 38.8 51.2 0.003 
MMSE, mean (SD) 29.0 (1.3) 27.5 (2.3) 21.2 (5.3) <0.001 
Meta-ROI Flortaucipir 
SUVR (SD) 
1.50 
(0.22) 1.61 (0.29) 2.32 (1.02) <0.001 
Whole Cerebral Cortical 
Florbetapir SUVR (SD) 
1.13 
(0.18) 1.18 (0.26) 1.37 (0.21) <0.001 
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Table 16. Minor allele distribution for variants retained in the regression models  
This table shows the percentage of subjects who had each copy number 
for the genes retained in any of the four regression models.  I display by 
diagnostic group. 
 
Variables CN (N=135) 
MCI 
(N=98) 
DEM 
(N=43) 
p-
value 
ABCA7 rs3752246 %0/1/2 68/30/2 76/22/2 70/28/2 0.747 
BIN1 rs744373 %0/1/2 50/39/10
✟
 42/46/12 58/37/5 0.361 
CLU rs11136000 %0/1/2 27/59/13
✟
 38/45/17 40/44/16 0.201 
CLU rs9331949 %0/1* 93/7 96/4 98/2 0.336 
EPHA1 rs11771145 %0/1/2 48/39/13 45/43/12 33/54/14
✟
 0.463 
PICALM rs3851179 %0/1/2 40/45/15 55/38/7 40/51/9 0.100 
SLC24A4/RIN3 rs10498633 
%0/1/2 64/33/2
✟
 67/22/10
✟
 63/35/2 0.030 
ZCWPW1 rs1476679 %0/1/2 47/44/10
✟
 48/41/11 70/28/2 0.078 
 
★Collapsed because minor allele homozygote frequency was <2%  
✟Does not add up to 100% due to rounding 
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Figure 11.  Association of the APOE e4 allele with tau deposition 
 
APOE e4 Association with [18F]Flortaucipir PET 
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Pooled Sample 
 In the pooled sample, the stepwise regression model achieved an R2 
value of 0.3294 (Table 17).  ABCA7 3752246 (coefficient=0.093, SE=0.055, p-
value=0.0907) and CLU rs9331949 (coefficient=0.200, SE=0.120, p-
value=0.0987) were associated with tau at a trend level. An exploratory analysis 
into the patterns of association can be seen in Figure 12 while the cluster-level 
and within-cluster peak effects can be seen in Table 18.  
  
  94 
Table 17. Regression Selected Variants in a Pooled Sample 
The selected genes under the AIC threshold of 0.157.  In addition to 
reporting model parameters, I show [18F]Flortaucipir meta-ROI SUVR by copy 
number of risk alleles 
 
 
  
Pooled Sample, Model R2 = 0.3294 
Covariates 
Selected 
Parameter 
Estimate 
Standard 
Error 
p-
value/FD
R-
correcte
d p-value 
[18F]Flort
aucipir 
SUVR by 
risk 
allele 
[18F]Flo
rtaucipi
r p-
value 
ABCA7 
rs3752246 0.093 0.055 
0.0907/0.
0987 
1.64/1.71/
2.13 0.096 
CLU rs9331949 0.200 0.120 0.0987/0.0987 1.66/1.77 0.472 
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Figure 12. Stepwise regression selected genes in a pooled sample (all diagnosis 
groups) 
SPM visualization of association patterns for regression selected genes. 
Due to the exploratory nature of this analysis, the p-value was set at an 
uncorrected p<0.01 and minimum cluster size of 50  
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Table 18. Cluster and within-cluster peak level effects for each diagnostic group 
This table shows FWE- and FDR-corrected cluster and peak-level values for variants which had at least one cluster 
FWE- or FDR-corrected p<0.05 (determined in SPM). 
 Cluster Level Peak Level 
Gene Variant 
FWE-
Corrected 
p-value 
FDR-
Corrected 
q-value 
Cluster 
Size, 
Voxels 
Uncorrected 
p-value T-value 
Uncorrected 
p-value 
Peak 
Talairach 
Coordinates 
x/y/z 
Brain Region 
Pooled Group 
ABCA7 
rs3752246 
0.001 0.004 3759 <0.001 4.75 <0.001 -50/-54/46 Left angular gyrus (BA39) 
0.001 0.004 3540 <0.001 4.57 <0.001 54/-42/50 Right supramarginal gyrus (BA40) 
0.010 0.029 2504 <0.001 4.27 <0.001 -44/16/48 Left premotor cortex (BA6) 
CLU rs9331949 0.031 0.063 1973 0.001 3.67 <0.001 -36/6/-24 Left temporopolar cortex (BA38) 
Cognitively Normal Group 
no clusters surviving correction 
Mild Cognitive Impairment Group 
CLU rs9331949 0.038 0.295 1334 0.001 4.49 <0.001 -40/-90/16 Left associative visual cortex (BA19) 
PICALM 
rs3851179 
0.001 0.001 2669 <0.001 4.36 <0.001 -46/-4/-26 Left temporopolar cortex (BA38) 
<0.001 0.001 8748 <0.001 4.01 <0.001 32/16/-34 Right temporopolar cortex (BA38) 
0.043 0.033 1303 0.001 3.59 <0.001 46/4/22 Right pars opercularis (BA44) 
SLC24A4/RIN3 
rs10498633 
0.039 0.052 1329 0.001 3.98 <0.001 -62/-32/-2 Left middle temporal gyrus (BA21) 
0.002 0.006 2222 <0.001 3.77 <0.001 30/-28/-22 Right fusiform gyrus (BA37) 
Dementia Group 
ZCWPW1 
rs1476679 <0.001 0.282 12855 <0.001 4.44 <0.001 -16/8/-20 
Left orbitofrontal cortex 
(BA11) 
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CN Sample 
 In the sample of CN subjects, the regression model achieved an R2 of 
0.1314 (Table 19). CLU rs9331949 (coefficient=0.200, SE=0.071, p-
value=0.0934) was associated with tau burden at a trend-level. Visualization of 
the patterns of association and the cluster and peak effects can be seen in 
Figure 13 and Table 18, respectively.  
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Table 19. Regression Selected Variants in a CN Sample 
The selected genes under the AIC threshold of 0.157.  In addition to 
reporting model parameters, I show [18F]Flortaucipir meta-ROI SUVR by copy 
number of risk alleles 
 
 
  
CN Sample, Model R2 = 0.1314 
Covariates 
Selected 
Parameter 
Estimate 
Standard 
Error 
p-
value/F
DR-
correcte
d p-
value 
[18F]Flort
aucipir 
SUVR by 
risk allele 
[18F]Flo
rtaucip
ir p-
value 
CLU 
rs9331949 0.200 0.071 
0.0934/0
.0934 1.50/1.63 0.076 
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Figure 13. Stepwise regression selected genes in the CN group 
SPM visualization of association patterns for regression selected genes. 
Due to the exploratory nature of this analysis, the p-value was set at an 
uncorrected p<0.01 and minimum cluster size of 50  
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MCI Sample 
 In the MCI sample, the regression model achieved an R2 of 0.2651 (Table 
20). BIN1 rs744373 (coefficient=0.086, SE=0.041, p-value=0.0366) was 
significantly associated with the Alzheimer’s specific tau deposition, while CLU 
rs11136000 (coefficient=-0.071, SE=0.038, p-value=0.0647), EPHA1 rs11771145 
(coefficient=0.069, SE=0.041, p-value=0.0946), PICALM rs3851179 
(coefficient=-0.079, SE=0.046, p-value=0.0853) and SLC24A4/RIN3 rs10498633 
(coefficient=-0.069, SE=0.040, p-value=0.0872) were associated at a trend level.  
CLU rs9331949 (coefficient=0.202, SE=0.134, p-value=0.1386) was included in 
the model by meeting the AIC model selection threshold. Visualization of the 
patterns of association and the cluster and peak effects can be seen in Figure 14 
and Table 18, respectively. 
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Table 20. Regression Selected Variants in an MCI Sample 
The selected genes under the AIC threshold of 0.157.  In addition to 
reporting model parameters, I show [18F]Flortaucipir meta-ROI SUVR by copy 
number of risk alleles 
 
  
MCI Sample, Model R2 = 0.2651 
Covariates 
Selected 
Parameter 
Estimate 
Stand
ard 
Error 
p-
value/F
DR-
correcte
d p-
value 
[18F]Flor
taucipir 
SUVR 
by risk 
allele 
[18F]Fl
ortau
cipir 
p-
value 
BIN1 rs744373 0.086 0.041 0.0366/0.1135 
1.55/1.6
6/1.61 0.225 
CLU 
rs11136000 -0.071 0.038 
0.0647/0
.1135 
1.66/1.6
1/1.48 0.116 
CLU rs9331949 0.202 0.134 0.1386/0.1386 
1.60/1.8
1 0.149 
EPHA1 
rs11771145 0.069 0.041 
0.0946/0
.1135 
1.56/1.6
5/1.64 0.339 
PICALM 
rs3851179 -0.079 0.046 
0.0853/0
.1135 
1.66/1.5
3/1.63 0.114 
SLC24A4/RIN3 
rs10498633 -0.069 0.040 
0.0872/0
.1135 
1.65/1.5
2/1.53 0.123 
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Figure 14. Stepwise regression selected genes in the MCI group 
SPM visualization of association patterns for regression selected genes. 
Due to the exploratory nature of this analysis, the p-value was set at an 
uncorrected p<0.01 and minimum cluster size of 50  
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DEM Sample 
 In DEM subjects, the regression model achieved an R2 of 0.2545 (Table 
21). ZCWPW1 rs1476679 (coefficient=0.518, SE=0.274, p-value=0.0665) was 
associated to tau deposition at a tend level. Exploratory visualization of the 
patterns of association, as well as cluster and peak effects, can be seen in 
Figure 15 and Table 18, respectively. 
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Table 21. Regression Selected Variants in a DEM Sample 
The selected genes under the AIC threshold of 0.157.  In addition to 
reporting model parameters, I show [18F]Flortaucipir meta-ROI SUVR by copy 
number of risk alleles 
 
DEM Sample, Model R2 = 0.2545 
Covariates 
Selected 
Parameter 
Estimate 
Standard 
Error 
p-
value/F
DR-
correcte
d p-
value 
[18F]Flort
aucipir 
SUVR by 
risk 
allele 
[18F]Flo
rtaucip
ir p-
value 
ZCWPW1 
rs1476679 0.518 0.274 
0.0665/0
.0665 
2.28/2.06
/6.81 <0.001 
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Figure 15. Stepwise regression selected genes in the DEM group 
SPM visualization of association patterns for regression selected genes. 
Due to the exploratory nature of this analysis, the p-value was set at a lenient 
uncorrected p<0.01 and minimum cluster size of 50  
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4.4. Discussion: 
 To my knowledge, this is the first comprehensive analysis of the 
association of the top 20 AD risk variants with tau burden. This work highlights 
the importance of modeling genetic associations in AD, as well as other complex 
diseases, in a polygenic fashion. I replicated associations to tau previously 
reported for ABCA7, BIN1, CLU, EPHA1, PICALM, and SLC24A4/RIN3, 
meanwhile identifying novel associations for ZCWPW1 140,181,184,207-217.  Like with 
my previous work 113,199, I also visualized the spatial associations using voxelwise 
regression maps and the table of FWE- or FDR- surviving clusters (Figures 12, 
13, 14, 15 and Table 18).  
 In total, I found 7 of the top 20 genes indicated in LOAD to have an 
association with tau burden.  To better understand the potential role each gene 
may play in tau pathology, I have listed a brief literature review that includes 
probable functions as well as a previous association to tau (if applicable) and any 
associations to amyloidosis or neurodegeneration from the earlier publications 
using a similar technique and sample. 
 
ABCA7 
 ATP-binding cassette subfamily A member 7 (ABCA7) encodes a 2,146 
amino acid member of the ABC transporter family comprised of proteins involved 
in lipid transport and plays a role in macrophage-mediated phagocytosis 156,218-
221. ABCA7 expression is associated with tangle density 184. In my earlier work, 
ABCA7 rs3752246 was associated with amyloidosis early in the disease course 
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(i.e., in CN and MCI) and with atrophy in the later disease stages (i.e. DEM) 
113,199.  Here, ABCA7 association to the AD meta-ROI was found only in the 
pooled sample.  
 
BIN1 
 Bridging integrator 1 (BIN1) encodes a 593 amino acid protein that may be 
involved with endocytosis of synaptic vesicles and trafficking as well as control of 
amyloid production 222.  Additionally, the gene product of BIN1 has been shown 
to directly interact with tau and further impact phosphorylation of tau 207. BIN1 
was recently associated with increased binding of [18F]Flortaucipir 208.  I failed to 
find BIN1 associations with amyloidosis or atrophy/hypometabolism in my prior 
work 113,199. Here I found significant BIN1 associations with tau in the MCI 
sample.  
 
CLU 
 Clusterin (CLU) encodes a 449 amino acid chaperone protein implicated 
in aggregation prevention of several proteins as well as in the regulation of cell 
proliferation 223-225. In regards to tau, carrying the rs11136000 minor allele was 
associated with CSF tau levels in AD patients and intracellular CLU was found to 
interact with tau in cell culture 210.  I previously found an association of the CLU 
rs9331949 variant with amyloidosis in DEM and hypometabolism in the CN and 
MCI 113,199. CLU rs11136000 was associated with amyloidosis and 
hypometabolism in the pooled sample.  I found an association of the rs9331949 
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variant with tau SUVR in the pooled, CN and MCI sample, while the rs11136000 
variant was associated at a trend level in the MCI sample. 
 
EPHA1 
 EPH receptor A1 (EPHA1) is a 976 amino acid receptor tyrosine kinase 
protein that binds ephrin-A ligands participating in intercellular signaling upstream 
of angiogenesis and regulation of cell proliferation 226-228, and as has recently 
been published, the Drosophila ortholog Eph was identified as a tau toxicity 
modulator 209. I previously found an association of EPHA1 rs11771145 to 
amyloidosis in a pooled, MCI, and DEM sample, to atrophy in a DEM sample and 
hypometabolism in a pooled sample 113,199.  I also found an association of 
another EPHA1 variant, rs11767557, to hypometabolism in a pooled sample 
113,199. I found that rs11771145 was associated with meta-ROI tau deposition in 
an MCI sample.   
 
PICALM 
 Phosphatidylinositol binding clathrin assembly protein (PICALM) encodes 
a 652 amino acid assembly protein which plays an essential role in clathrin-
mediated endocytosis and specifically in the clearance of autophagy substrates 
like tau and amyloid precursor protein C-terminal fragment 217,229,230. PICALM 
overexpression significantly increased tau accumulation measured in cell culture 
as well as in an in vivo zebrafish model 217.  PICALM was associated with 
  109 
amyloidosis in a CN sample in my earlier work 113,199. I found that PICALM was 
associated with tau burden in an MCI sample at a trend level (p=0.0853). 
 
SLC24A4/RIN3 
 Solute carrier family 24 member 4 (SLC24A4) encodes a 622 amino acid 
protein involved in potassium-dependent sodium and calcium exchanger 231, 
while the other gene located near the risk loci, Ras and rab interactor 3 (RIN3), 
encodes a 985 amino acid protein involved in guanine nucleotide exchange with 
small GTPases 187,232. Additionally, peripheral hypomethylation of RIN3 is 
associated with tangle pathology 214. I previously found that SLC24A4/RIN3 
rs10498633 was associated with atrophy in a pooled, MCI and DEM sample, as 
well as with hypometabolism in a pooled and CN sample 113,199.  It seems that 
this variant is associated with tau and neurodegeneration to some degree 
through the entire cognitive spectrum, a fact that may indicate a gene of relative 
importance.  I found that rs10498633 was associated with tau in the MCI sample.  
 
ZCWPW1 
 Zinc finger CW-type and PPWP domain containing 1 (ZCWPW1) encodes 
a 648 amino acid protein with a potential role in epigenetic regulation 192,233. I 
previously found that ZCWPW1 rs1476679 was associated with amyloidosis in a 
pooled and DEM sample, as well as with atrophy in an MCI sample 113,199.   Here, 
I found a novel association of rs1476679 with AD meta-ROI tau SUVR in the 
DEM sample.   
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4.5. Strengths and limitations: 
This study has several strengths and limitations of which merit discussion. 
One of the main strengths lies in the rigorous clinical, biomarker, and genetic 
characterization of all individuals enrolled in ADNI. ADNI uses standardized 
subject assessment, data collection and quality control practices as well as an 
imaging normalization to bring images from different scanner types and locations 
to their closest alignment. Another strength of ADNI is that it is a well-
characterized cohort. A major limitation of the study is that I report only cross-
sectional analyses, making it difficult to determine with absolute certainty that 
specific genetic variants exert stage-specific effects. However, leveraging the full 
dementia continuum, I suggest that there are differential early and late genetic 
influences on cortical tau burden. Another limitation of the work is the sample 
size, which was not large enough to visualize spatial associations in more than 
an exploratory fashion. I also believe the small sample size prevented finding 
more significant genes than BIN1. As more subjects in ADNI are scanned with 
[18F]Flortaucipir and more genotyping data is made available, the growing sample 
size should allow for more stringent thresholding and more power to detect 
significant associations of the variants with tau. Finally, ADNI is a research cohort 
that is not entirely representative of the general population, thus, the continuation 
of this study will aim to validate my findings in a large, independent, longitudinal 
cohort. 
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4.6. Conclusions: 
 Using a multivariable regression modeling technique across the cognitive 
continuum, I found associations of 7 of the top 20 AD risk genes to tau deposition 
in an AD-specific meta-ROI.  Furthermore, using voxelwise regression, I found 
spatial association patterns, which should warrant more consideration as the 
sample size is increased in future iterations of this analysis.  
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Chapter 5. Summary and Future Directions 
 Studying Alzheimer’s disease in vivo requires reliable and accessible 
disease biomarkers. Here, I report several studies that utilize neuroimaging 
features as biomarkers to better understand the driving factors of the 
heterogeneity seen in clinically diagnosed Alzheimer’s age of disease onset, 
biomarker abnormalities and genetic risk.  I first analyzed the impact of amyloid 
burden and age of cognitive symptom onset on neurodegeneration and tau 
burden relative to cognitively normal subjects. I then utilized an imaging genetics 
approach, looking at gene variant associations with both neurodegeneration and 
tau burden.  
5.1. Neurodegenerative Changes in Early & Late-Onset Cognitive 
Impairment with and without Brain Amyloidosis: 
Summary 
Chapter 2 is a neuroimaging study that aimed to determine the extent of 
tau and neurodegenerative pathophysiology measured with tau PET 
([18F]Flortaucipir), FDG PET and MRI in early-onset (EO) and late-onset (LO) 
ADNI cohorts stratified by amyloid positivity. To control for disease severity, I 
also stratified by clinical diagnosis, resulting in eight cognitively impaired groups 
and one amyloid negative CN group which was directly compared against all 
groups; EOADMCI, EOADDEM, EOnonADMCI, EOnonADDEM, LOADMCI, LOADDEM, 
LOnonADMCI and LOnonADDEM.  I included additional analyses comparing the LO 
and EO groups to either the older or younger half of the CN group, respectively. 
Voxelwise regression maps were made, comparing each group to CN subjects 
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and for all three modalities. Additionally, interpretation of voxelwise maps 
comparing groups of unequal sample sizes can be misleading. I, therefore, 
derived β-coefficient maps, which display effect sizes in each comparison. 
Compared to EOADMCI, LOADMCI had significantly fewer years of 
education, while both EOAD groups had a significantly higher percentage of 
APOE e4 homozygotes compared to LOAD subjects. Across the three 
modalities, all AD groups show large clusters of neurodegeneration and tau, 
though the MCI groups show less than DEM. The DEM groups largely show 
significance across the brain.  This, in particular, underscores the importance of 
the coefficient maps, as both EO groups had much larger effect sizes than their 
diagnostic LO counterparts across the three modalities.   
The EOnonADMCI group had a higher proportion of APOE e4 carriers 
compared to the LOnonADMCI group.  While I failed to find significant 
neurodegeneration in EOnonADMCI, I observed significant hypometabolism in 
EOnonADDEM.  The lack of findings, particularly in the EOnonADDEM subjects may 
be because this group is largely heterogeneous. 
LOnonAD, on the other hand, showed significant atrophy and 
hypometabolism across temporal and frontal lobes, a pattern of 
neurodegeneration seen in both primary age-related tauopathy (PART) and 
hippocampal sclerosis with TAR-DNA binding protein 43 (TDP-43) inclusions 
(HS-TDP-43) 95,96. However, due to the lack of findings on the tau scans, I 
believe the most likely etiology of the LOnonAD subjects to be limbic-
predominant age-related TDP-43 encephalopathy (LATE) 97. 
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Future Directions 
 To further the work presented here, I would first begin with the inclusion of 
longitudinal imaging biomarkers.  I believe this would greatly inform the study, 
filling gaps where I may now only speculate on what the biological process is.  
For example, the EOnonAD subjects who show no tau or neurodegeneration 
may still show an increased rate of tau accumulation and/or neurodegeneration 
compared to CN and LOnonAD subjects.  Beyond that, the pattern of deposition 
or neurodegeneration seen in LOnonAD’s may provide the information needed to 
understand more about the potential etiology of these subjects.   
 In addition to longitudinal imaging, a more complete cognitive assessment 
of the nonAD subjects would be helpful.  Prospective studies focused on the 
nonAD subjects should include cross sectional and longitudinal batteries that 
may help to identify specific etiologies based on varying affected domains.   
I believe adding a post-mortem validation for each of the LOnonAD (really 
all of the nonAD) subjects would be valuable.  I would expect both nonAD groups 
to be heterogeneous, though I have specifically identified TDP-43 pathology as a 
potential driver of the signal seen in LOnonAD.  TDP-43 is often found to have an 
age-related association; therefore, it would be hard to speculate whether or not 
this would be expected to be found in EOnonAD subjects as well.  
 The addition of other biomarkers to this analysis may also prove useful in 
ascertaining the nature of the nonAD etiology.  The most obvious additions are 
plasma, and CSF markers of AD pathophysiology and neuronal damage, such as 
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Aβ, tau, neurofilament light chain, various metabolomic and lipidomic measures 
and measures of inflammation. Imaging markers of neuroinflammation or 
immune response are still in their relative infancy and currently are not even well 
understood.  However, should one become available, it may be prudent to 
include. Beyond molecular imaging there are more complex MR sequences that 
would give information on white matter tract changes (diffusion imaging) and/or 
functional changes (functional MRI). 
 Finally, I believe future studies should include a genetic component, an 
intentionally vague suggestion because the genetic risk of sporadic EOAD is 
essentially unknown at this point.  There are some who believe that there may 
not be much of a difference between the variant risk in EO vs LOAD, as the 
underlying pathology remains largely the same.  I would argue that I am unsure 
even to what degree genetics plays in EOAD, be it more or less of a driving 
factor than in LOAD.  I believe the differences in disease severity, in progression 
and most of all, in onset, are all factors that likely have a genetic component to 
them, which I believe crucial to not only understanding EOAD, but LOAD.  To do 
this, I would start with GWAS to identify new hits that may explain some of the 
variability between EO and LOAD.  I believe it would also be important to repeat 
a similar imaging genetics study presented in chapters 3 and 4 to measure 
relative variant contributions to amyloid, tau and neurodegeneration.  
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5.2. The effect of the top 20 Alzheimer’s disease risk genes on gray matter 
density and FDG PET brain metabolism: 
Summary 
Chapter 3 explored the genetic risk alleles associated with imaging 
measures of neurodegeneration (FDG PET and MRI).  I included risk variants 
identified in genome-wide association studies (GWAS) and meta-analysis of 
GWAS as significantly associated with AD, as well as variants near those found 
through GWAS that have previously been associated with brain amyloidosis 78-
80,196-198.   
Following the reduction of variants after linkage disequilibrium analysis, all 
remaining 27 were included in multiple linear regression models with the variants 
included as predictors and either posterior cingulate cortex (PCC) SUVR (FDG) 
or gray-matter density (GMD) (MRI).  Four models were run in each modality to 
tease apart the potential changing gene effects across the cognitive continuum 
(Pooled, NC, MCI and DEM models). The variants selected in the regression 
models were replicated using voxelwise regression to display patterns of 
association. 
In the MRI analyses, I found SLC24A4/RIN3 rs10498633 was significantly 
associated with GMD but found no associations in the NC group. However, both 
SLC24A4/RIN3 rs10498633 and ZCWPW1 rs1476679 were significantly 
associated with GMD, while CELF1 rs10838725 was trending in the MCI group. 
ABCA7 rs3752246, EPHA1 rs11771145 and INPP5D rs35349669 were 
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significantly associated with GMD in the DEM sample, while SLC24A4/RIN3 
rs10498633 showed a trend-level association. 
In the FDG PET analyses, EPHA1 rs11767557 was significantly associated 
with hypometabolism in the pooled sample, while MS4A6A rs610932, PTK2B 
rs28834970 and SLC24A4/RIN3 rs10498633 were associated at a trend-level. In 
the NC control group, CD2AP rs9349407, NME8 rs2718058 and SLC24A4/RIN3 
rs10498533 were significantly associated with hypometabolism in PCC. Also in the 
NC group, CELF1 rs10838725, CR1 rs12034383 and DSG2 rs8093731 had 
trending significance. In the MCI and DEM cohort, only CLU rs9331949 and 
SORL1 rs11218343, respectively, showed trend-level associations.  
Several variants show diagnosis-specific associations, which often 
followed the hypothetic biomarker progression proposed by Jack et al.114. In this 
model, neurodegeneration follows the buildup of amyloid and tau protein and 
begins in the late asymptomatic stages between NC and MCI 114. A fitting 
example of this is seen in the ABCA7 and EPHA1 genes.  Both genes were 
significantly associated with brain amyloidosis in my previous work, with their 
largest effect in the MCI cohort 153. Here, I found that both ABCA7 and EPHA1 
associated with neurodegeneration in the DEM group, which follows the 
biomarker progression curve. 
The reported associations of ABCA7, INPP5D and ZCWPW1 to GMD, and 
of CD2AP to brain metabolism are novel.     
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5.3. Association of the top 20 Alzheimer’s disease risk genes with 
[18F]Flortaucipir PET: 
Summary  
 Chapter 4, like in the previous chapter, utilizes an imaging genetics 
approach to study associations of the top 20 AD risk genes, this time with 
[18F]Flortaucipir PET.  As with before, genes were included in a multiple 
regression analysis as predictors while [18F]Flortaucipir PET meta-ROI SUVR 
was used as an outcome. 
 The meta-ROI used was an a priori AD-specific region determined by 
Clifford Jack and included the size-weighted Freesurfer regions corresponding to 
entorhinal, amygdala, parahippocampal, fusiform, inferior temporal, and middle 
temporal ROIs 204,205.  Final regression outputs were reproduced in imaging 
space to visualize spatial patterns of gene variant associations. 
 I found there were significantly more male participants in the MCI group 
than in either CN or DEM and that DEM subjects had significantly less education 
than the other two groups. I also found that among all variants retained in the 
models, only SLC24A4/RIN3 was significantly different in allele distribution 
among diagnostic groups, having more homozygous minor allele carriers in the 
MCI group. APOE4 showed significant association with tau in the pooled, CN and 
MCI sample while only minimally so in the DEM group, even though there were 
significantly more homozygous carriers of the e4 allele in the DEM group. 
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 Results from the regression analysis showed trend-level associations to 
tau for both ABCA7 rs3752246 and CLU rs9331949 in the pooled sample, as well 
as CLU rs9331949 in the CN sample.  In the MCI group, BIN1 rs744373 was 
significantly associated, while CLU rs11136000, EPHA1 rs11771145, PICALM 
rs3851179 and SLC24A4/RIN3 rs10498633 were associated at a trend-level to 
tau.  In the DEM sample, only a single variant was selected, ZCWPW1 
rs1476679, which was associated with tau at a trend-level.  As with my previous 
work, I also visualized associations using voxelwise regression maps in SPM 
113,199. 
 Despite no genes surviving FDR-correction (likely due to the smaller 
sample size), I was able to reproduce the associations to tau previously reported 
for ABCA7, BIN1, CLU, EPHA1, PICALM, and SLC24A4/RIN3 140,181,184,207-217. 
The association of ZCWPW1 to tau pathology has not been reported previously.  
In total, I found 7 of the top 20 genes indicated in LOAD to have an association 
with tau burden. 
Future Directions for both 5.2. and 5.3. 
 Given the opportunity to further expand on this work I would first and 
foremost repeat the analysis using longitudinal imaging biomarkers.  As 
mentioned previously, GMD does correlate with atrophy but the two are not 
synonymous.  Measuring atrophy, instead, I believe would give more power to 
the study.  The same can be true as well with both PET modalities i.e. measuring 
a decrease in brain metabolism and an increase in tau burden vs. at a single time 
point relative to a mean.   
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 Specific to the imaging analysis of [18F]Flortaucipir PET, I would 
dramatically increase the sample size to more closely match that of the MRI and 
FDG PET analysis.  This, of course, would largely get rid of any spurious 
associations and would hopefully result in more variants surviving multiple 
comparisons correction.   
 Additionally, I would include more variants in future analyses that have 
been identified since the inception of these studies.  The current analysis is 
based on the GWAS and meta-analysis of GWAS from papers published in the 
early 2010s, which are nearly a decade old.  Recently, there have been several 
massive GWAS/GWAX studies published which identify 13 new risk loci, not to 
mention slightly older GWAS which have occurred between 2013 and now 234-236.  
Inclusion of these as well as other genome-wide-significant loci would enrich the 
results and perhaps explain even more of the variance. 
 Finally, I believe it is necessary to continue this analysis across a variety 
of other races and ethnicities.  We know that there are disparities in disease 
prevalence and severity across these groups for a variety of reasons, not the 
least of which is genetic 237-240. Future studies should first include multiple GWAS 
of each homogenous population.  This, of course, has been difficult in the past.  
The results of these various GWAS would likely output several novel loci 
(possibly explaining some of the variability across race and ethnicity) as well as 
several overlapping loci (highlighting SNPs whose functions are central to the 
disease process). In line with this as well, is the sex-specific AD disparity, as we 
know women have a much greater risk.  I believe GWAS hits would potentially be 
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able to explain this.  Whether entirely new loci would appear or whether it would 
be the same loci with much greater effect sizes is unknown.  The presented 
imaging genetics approach may be an effective route to parsing sex-specific 
differences for the currently known genome-wide significant loci and at the very 
least, in highlighting the variable effect size differences in genetic associations 
between male and female patients.   
5.4. Conclusion: 
 The above work highlights the versatility of neuroimaging biomarkers to 
study the pathophysiology variations of clinically diagnosed AD and genetics of 
AD.  Here, I studied tau and neurodegeneration in subjects divided by age of 
onset and amyloidosis.  In amyloid positive subjects, earlier age of onset meant 
greater tau burden and neurodegeneration than their late-onset counterparts.  
For amyloid negative subjects, however, only the late-onset group displayed any 
significant neurodegeneration, which was in a non-Alzheimer’s pattern and was 
suggestive of TDP-43 with hippocampal sclerosis.  Using a neuroimaging 
genetics approach, I found variants of the top 20 Alzheimer’s genes associated 
with FDG and [18F]Flortaucipir PET SUVR and MRI measures of medial temporal 
lobe thickness.  Beyond replicating associations seen previously for many of the 
variants I found novel variant associations for all three modalities. Taken 
together, these results have 1) highlighted just how much age of onset impacts 
the progression of AD and indicated several groups which warrant future study 
and 2) identified several gene variants which may potentially garner further 
attention as drug targets or warrant further study on their own   
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